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Alzheimer’s Disease (AD) is a degenerative neurological disease process that results 
in cognitive and functional declines and ultimately results in death. The pattern and course of 
cognitive and functional decline has been well characterized in AD, however little is known 
about the interactions between the symptoms. Network Analysis is a recently developed 
mathematical approach of examining the interactions between symptoms, by exploring the 
covariance of symptoms. The current study utilized network analysis to examine the 
multivariate structural dependencies among cognitive domains known to be affected in 
Alzheimer’s disease. The sample consisted of 864 older adults (60-90 years old), selected 
from the National Alzheimer’s Coordinating Center (NACC) Database, that were assessed 
over four serial cognitive assessments, each conducted approximately one year apart. The 
sample was divided into two groups (432 per group). Both groups were cognitively normal at 
baseline assessment, with one group remaining cognitively normal (Control group) and one 
going on to develop either Mild Cognitive Impairment (MCI) or Dementia due to AD 
(Converter group) over the course of the four assessments. The participants completed a 
neuropsychological assessment with tests known to be sensitive to AD, which included a 







memory, and language. The relationship between performance on these measures was 
examined using Network Analysis. The Converter group was also subdivided by sex and the 
networks of men and women were compared. It was hypothesized that there would be 
differences in the network structure of these cognitive test between the groups both before 
criteria for a cognitive diagnosis was made, as well as after the Converter group was 
diagnosed with AD.  It was also hypothesized that the network structure of cognitive tests 
would differ for men and women with AD. Finally, it was hypothesized that the network 
structure of these cognitive tests would differ over time for the Converter group. Results 
indicate that there are differences in the network structure of cognitive tests between the 
Control and Converter groups even before diagnosis and that this difference becomes more 
significant over time. However there is not a significant difference between men and women 
in the Converter group, in terms of network structure. Finally within the Converter group, 
while the difference in network structure appears to become more prominent over time, it is 
not significantly difference over the four years assessed in the current study. These findings 
provide a clearer understanding the impact of AD on the changes in cognitive functioning 
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Chapter 1: Introduction 
Alzheimer’s Disease (AD) is degenerative neurological disease process that affects over 
5 million older adults in the United States each year. Costs of AD have risen to over 170 billion 
dollars annually. As the average age of the population in the United States increases, this 
disorder may soon reach epidemic proportion (Alzheimer’s Association, 2010; Hebert, Scherr, 
Bienias, Bennett, & Evans, 2003). The neuropathological changes associated with AD affect a 
number of brain regions and include the formation of senile plaques and neurofibrillary tangles 
that result in atrophy of the medial temporal lobes, an area associated with memory and 
semantic knowledge (Hyman, Van Hoesen, Damasio, & Barnes, 1984). The typical disease 
progression is characterized by declines in cognitive and functional abilities. These declines 
occur over an average of 10 years and often result in full debilitation that ultimately leads to 
death due to related health complications (Hebert et al., 2003). 
The diagnostic criteria and classification of AD has evolved over time and the latest 
edition of the Diagnostic Statistical Manual (DSM-5) includes the diagnoses of Major or Mild 
Neurocognitive Disorder with specification of certainty (i.e. possible or probable) and etiology  
(e.g., AD, vascular, dementia with Lewy bodies, etc.) (American Psychiatric Association, 
2013). There is extensive research that has explored the typical pattern and course of 
progression of cognitive declines in dementia. However, there have been few studies that 
explore the relationship between the symptoms domains and the relationship between those 
domains and individual factors.  Furthermore, none have done so using network analysis.  
Network analysis is a statistical method of examining the inter-connection of individual 
cognitive symptom domains, and determining if some domains are more central than others 







individual factors such as sex or years of education influence the structure of the network. 
Network analysis also allows for examining if there is a particular symptom domain that is more 
central in the network or if one symptoms domain drives global increases in the other symptom 
domains. Furthermore, the use of time series network analysis allows for examining how the 
network structure changes over the course of time. Using network analysis to examine changes 
in cognition over time would contribute to the overall knowledge of how AD progresses, and 
the impact of individual factors on that progression. This has significant implications for 
understanding the progression of AD and treatment planning. As such, the current study seeks 
to explore the differences in network structure of cognitive symptoms known to decline in AD 
between individuals with normal cognition, mild neurocognitive disorder (MCI) due to AD, and 
major neurocognitive disorder due to AD (dementia). The current study also seeks to more 
clearly characterize the differences in the progression of AD between men and women by 
comparing changes in the network structure longitudinally for individuals with mild (MCI) or 
major neurocognitive disorder (Dementia) due to AD. Additionally, we will aim to establish 
how the network structure of cognitive abilities, affected in AD, differs for those with MCI or 
Dementia due to AD, as compared to those with normal cognitive functioning. Findings will not 
only contribute to the current understanding of the course and progression of cognitive decline 
in AD, results will also increase understanding of the relationship between the cognitive 
domains affected in AD and how they change in relation to one another. Findings may help to 
better understand factors that contribute to individual differences in pattern and course of 








Chapter 2: Literature Review 
Alzheimer’s Disease  
Alzheimer’s Disease (AD) is degenerative neurological disease process that affects over 
5 million older adults in the United states each year, costing over 170 billion dollars annually. 
With the average age of the population in the United States increasing, concerns have been raised 
that AD may soon reach epidemic proportion (Alzheimer’s Association, 2010; Hebert et al., 
2003). As a result, there has been extensive research done to better understand the cause, 
progression, and impact of AD.  From a neurocognitive standpoint, the pattern and course of 
cognitive decline seen in AD is rather consistent (Bondi, Edmonds, & Salmon, 2017a). While 
there are some occasions when the cognitive and behavioral presentation is atypical, most 
commonly, individuals present with impairments in memory that progress over time (Bondi, 
Edmonds, & Salmon, 2017b). Specifically, impairments in encoding and storage of new 
memories has been found in individuals with AD (Hodges & Patterson, 1995). Using 
neuropsychological assessments, this pattern of memory impairment can be distinguished from 
attention based memory impairments (Bondi et al., 2014; Buschke, Sliwinski, Kuslansky, & 
Lipton, 1997). In addition to memory decline, many individuals also experience language 
impairments early in the disease process. Loss of sematic knowledge results in word finding 
difficulties and impairments in sematic fluency (Nebes, 1989; Hodges & Patterson, 1995). 
Visuospatial abilities (Cronin-Golomb, & Amick, 2001) and executive functions (Bondi, 
Monsch, Butters, Salmon, & Paulsen, 1993; Lafleche & Albert, 1995; Perry, 1999) are also 







Ultimately, cognitive declines progress to more global impairment over the course of the 
disease. Given the progressive nature of the disease, the latest edition of the DSM, Diagnostic 
and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) includes the diagnoses of 
Major or Mild Neurocognitive Disorder to distinguish the level of impairment the individual has 
(American Psychiatric Association, 2013). The distinction between Major or Mild 
Neurocognitive Disorder are similar in many ways to the previously used criteria for 
distinguishing Dementia and MCI. Due to these similarities, these terms are often used 
interchangeably in the literature on AD. In addition to the distinction of Major or Mild 
Neurocognitive Disorder, the DSM-5 also includes the use of modifiers which indicate the 
etiological cause of the cognitive decline. Finally, the DSM-5 includes a specifier which 
indicates the certainty of the etiological cause. For instance, a specifier of “possible” or 
“probable” is used when the etiology is thought to be AD. Taken together, the diagnostic criteria 
included in the DSM-5 aims to provide more diagnostic clarity, which in turn provides patients 
and their loved ones more insight into what should be expected as the disease progresses.  
Neurocognitive Disorder  
As mentioned above, the lasted edition of the DSM (DSM-5) draws a distinction between 
Mild and Major Neurocognitive Disorder, with the primary difference being the individual’s 
level of impairment in daily functioning or Activities of Daily Living (ADLs). In order to meet 
criteria for Mild Neurocognitive Disorder, the individual must:  
A. Evidence of significant cognitive decline from a previous level of performance in one 
or more cognitive domains (complex attention, executive function, learning and 
memory, language, perceptual-motor, or social cognition) based on:  







there has been a significant decline in cognitive function; and 
2. A substantial impairment in cognitive performance, preferably documented by 
standardized neuropsychological testing or, in its absence, another quantified 
clinical assessment.  
B. The cognitive deficits do not interfere with capacity for independence in everyday 
activities (i.e., complex instrumental activities of daily living such as paying bills or 
managing medications are preserved, but greater effort, compensatory strategies, or 
accommodation may be required).  
C. The cognitive deficits do not occur exclusively in the context of a delirium. 
D. The cognitive deficits are not better explained by another mental disorder (e.g., major 
depressive disorder, schizophrenia) 
 The criteria for Major Neurocognitive disorder are identical, except for criteria B, which 
states, “the cognitive deficits interfere with independence in everyday activities (i.e., at a 
minimum, requiring assistance with complex instrumental activities of daily living such as 
paying bills or managing medications).”  As such, for AD, Mild Neurocognitive Disorder is a 
precursor to Major Neurocognitive Disorder (American Psychiatric Association, 2013; Edmonds 
et al., 2019; Morris et al., 2001), with the latter diagnosis made once the disease progresses to the 
level when individuals have lost the ability to care for their daily needs.  
 Mild and Major Neurocognitive Disorder are umbrella terms that refers to decline in 
cognition and adaptive (for major) functioning that result from a neurodegenerative process. 
There have been a number of subtypes identified, each of which is associated with a unique 
neurodegenerative disease process and the resulting decline in functioning and cognition 







for specification of the etiology subtype. The etiology is determined based on time course, 
domains affected, associated symptoms, patient health and neurologic history (e.g. history of TBI 
or psychiatric history) and in some cases, biological markers. The DSM-5 criteria also includes a 
qualifier of certainty in the etiology and in the case of AD can be possible or probable AD 
(American Psychiatric Association, 2013). The accuracy of the clinical criteria for probable AD, 
when diagnosed in a specialized memory disorders centers, generally exceeds 85%. However, 
despite this level of accuracy, a final diagnosis can only occur after examination of the brain 
upon autopsy and is based on the density of senile plaques and neurofibrillary tangles. 
Alzheimer’s Disease is among the most prevalent  of the degenerative subtypes and is diagnosed 
primarily based on cognitive, behavioral, and functional symptoms (American Psychiatric 
Association, 2013). Additionally, there are known biomarkers associated with AD that can aid in 
identifying AD as the etiology of the neurocognitive disorder.  
Pattern and Course of Progression  
 The declines in cognitive functioning that occur in the early stages of AD are associated 
with neuropathological changes in the medial temporal lobes and progresses frontally. Because 
the medial temporal lobes are the brain regions that mediate language and memory, individuals 
with Alzheimer’s Dementia (AD) generally present initially with changes in memory, language, 
and semantic processing, while cognitive deficits associated with frontal lobe pathology appear 
later in the course of the disorder. As the disease progresses and disease pathology spreads 
throughout the brain, impairments become more global in nature. Research has implicated beta 
amyloid plaques and tau tangles (Braak & Braak, 1991) as the cause of neurodegeneration. For 
most individuals the neurodegenerative process progresses slowly, and a significant disease load 







decline seen in AD has been well studied, and the typical pattern involves early impairments in 
learning, memory, and language, with later declines in frontal lobe functions such as attention, 
working memory, and executive functions (Braak & Braak, 1991). However the relationships 
between these domains and the affect that decline in one domain has on the others has not been 
examined.  
Sex-related Differences 
  Sex-related differences have been identified in both the prevalence and rate of 
progression of AD. The prevalence of AD has been found to be significantly higher in women as 
compared to men. Specifically, research has found the lifetime risk of dementia due to AD was 
approximately twice as high in women (12%) as compared to men (6.3%)  (Plassman et al., 
2007; Seshadri et al., 1997). Most recently, census estimates revealed nearly two-thirds of the 
older adults diagnosed with AD are women (Hebert, Weuve, Scherr, & Evans, 2013). 
Researchers have attempted to account for this disparity by examining sex differences in 
incidence, progression (Hebert, Scherr, McCann, Beckett, & Evans, 2001; Letenneur et al., 1999; 
Liu et al., 1998; Kivohara et al., 1996; Roberts et al., 2014), and responsiveness to treatments 
(Mielke, Vemuri, & Rocca, 2014).  
One commonly cited explanation for higher prevalence in women is the longer average 
life span for women as compared to men which results in a longer period of risk. This 
explanation has been supported by several researchers, including Plassman et al. (2007) who 
found that when age and education were controlled, women were are no higher risk than men for 
developing dementia due to AD. Seshadri and colleagues (1997) also accounted for this 
difference based on the longer life expectancy of women as compared to men. More recently, 







originally thought. Several alternative explanations include hormonal differences, cognitive 
reserve, education, and other biological explanations (Laws, Irvine, & Gale, 2018). Laws et al. 
(2018) argue that there is evidence that not only are rates of AD higher in women, but women 
seem to decline at a more rapid pace, and also show greater impairment than men. These 
differences cannot be accounted for by longer life span and therefore other factors must be 
involved.  
 There have been mixed findings regarding hormonal differences between men and 
women is as a possible explanations for the sex differences. While, some studies find positive 
effects, others have found negative effects of hormones on AD. One of the largest studies that 
has been conducted on the effects of hormones on AD is the Women’s Health Initiative Memory 
Study (WHIMS). This study involved 7479 postmenopausal women (Rapp et al., 2003; 
Shumaker et al., 2003). Four thousand five hundred and thirty two women with natural 
menopause (intact uterus) were randomly assigned to groups comparing conjugated equine 
estrogen (CEE) and medroxyprogesterone (MPA) to a placebo (Rapp et al., 2003). Data from the 
WHIMS demonstrated a higher incidence of dementia and greater cognitive decline in the group 
using hormone replacements as compared to the placebo group. In contrast, several RCTs have 
shown when healthy postmenopausal women treated with 17β –estradiol (E2) were compared to 
controls, hormone use was associated with less decline in verbal memory (Bagger, Tanko, 
Alexandersen, Qin, Christiansen, for the PERF Study Group, 2005; Dumas, Hancur-Bucci, 
Naylor, Sites, & Newhouse, 2008; Silverman et al., 2011; Tierney et al., 2009).  The 
inconsistency between these findings has been explained by using the “healthy-cell bias” (Chen, 
Nilsen, & Brinton, 2006), which suggests that E2 selectively benefits neurons that are healthy. 







neuronal cell degeneration has begun. 
 Sex differences in AD have also been explored in terms of metabolic differences. Malpetti 
and colleagues (2017) examined brain hypo-metabolism differences between men and women in 
the context of cognitive reserve (e.g. education and occupational level). This study included 
healthy controls (n = 225) and patients with AD (n = 282), and found, within the AD group, there 
were  differences in the correlations between education and occupation levels and brain hypo-
metabolism. Specifically, there was a posterior temporal-parietal association in males and a 
frontal and limbic association in females. This finding suggests that networks involvement 
differs between men and women. The metabolic connectivity for both controls and those with 
AD were similar, however there are  differences in network activation. Specifically, there was 
greater efficiency in the posterior default mode network for males, while the anterior frontal 
executive network had greater efficiency for females (Malpetti et al., 2017).  
 In further attempts to better characterize the  differences in AD, researchers have looked 
to the underlying AD pathology for explanations for the observed sex differences (Filon et al., 
2016). Filon and colleagues (2016) conducted full neuropathological examinations on 1028 
deceased individuals with AD. Results founds no difference by in the age of dementia onset. 
However, they did find that women were more likely to proceed to very severe cognitive 
impairments (Mini-Mental State Examination score of 5) as well has more significant 
neuropathological changes (less than Braak stage VI neurofibrillary degeneration). Regarding the 
pathological differences, there were not significant differences in the median neuritic plaque 
densities in men and women, while women did have significantly greater tangle density scores. 
This study also showed a significant difference in the brain weight between females with AD as 







This difference remained significant even when accounted for age, disease duration, and 
comorbid conditions. Based on these findings, Filon and colleagues (2016) argue that women 
have more severe neurofibrillary degeneration, and greater loss of brain parenchyma, which is 
one reason for the  disparity in the rate of progression and severity of AD. 
Neuropathology of Alzheimer’s Disease 
As discussed above, the neuropathological changes of AD occur in the medial temporal 
lobes initially and then spreads globally (Korf, Wahlund, Visser, & Scheltens, 2004).  The 
typical disease progression is characterized by decline in cognitive and functional abilities 
(Hebert et al., 2003). The neuropathological changes associated with AD include the senile 
plaques and neurofibrillary tangles. The plaques are thought to be formed as a result of mis-
folding of a beta amyloid proteins (A-beta), causing toxic amyloid fibrils.  This process can 
begin to occur as many as 20 – 30 years prior to the manifestation of any clinical symptoms of 
the disease. These abnormal proteins build up in the medial temporal lobes, frontal lobes, 
anterior cingulate, posterior cingulate, precuneas and striatum (Nestor, Fryer, Smielewski, & 
Hodges, 2003; Pengas, Hodges, Watson, & Nestor, 2010).This build up eventually sets off a 
cascade effect resulting in problems with phosphorylation of the microtubule-associated protein 
(MAP) (Iqbal, Liu, & Gong, 2018). Tau is a type of MAP that stimulates tubulin assembly into 
microtubules in the brain and is normally occurring in healthy brains (Weingarten, Lockwood, 
Hwo, & Kirschner, 1975). However when abnormal hyperphosphorylation of tau occurs, this 
causes the tau to be toxic and contributes to neurodegeneration. The toxic function that occurs as 
a result of this hyperphosphorylation cannot then compensated for by other MAPs (Liu et al., 
2007).Once the hyperphosphorylation occurs, the abnormal tau is polymerized into highly 







NFTs that give rise to cell death. The mechanisms that result in the senile plaques and 
neurofibrillary tangles have been targeted for pharmacological interventions, however a cure has 
not yet been identified.  
Biomarkers 
Given these neuropathological underpinnings of AD, researchers have worked to identify 
biomarkers of AD. Biomarkers, simply put, are measurable variables, either physical, chemical, 
or anatomical variables that provide insight into the disease state. Specific to AD, two categories 
of biomarkers discussed in the research include those associated with amyloid accumulation, and 
those associated with neurodegeneration. The core biomarkers for AD provide evidence of 
amyloid pathology (Aβ40 / Aβ42 extracellular accumulation) and/or intracellular depositions of 
neurofibrillary tangles (hyperphosphorylated Tau inclusions). These biomarkers therefore serve 
to identify neuropathological features of AD in individuals that are still living. Previously, this 
type of neuropathology could only be detected on biopsy or necropsy (Menéndez González, 
2014). In addition to being able to more easily detect these signs of AD pathology in living 
individuals, use of biomarkers also allows for monitoring the progression of the neuropathology.  
Cerebral Spinal Fluid 
A number of different methods of measuring these biomarkers have been developed over 
the past 20-30 years, including cerebral spinal fluid (CSF) testing and neuroimaging. 
Specifically, given the unique role of CSF in the nervous system, it is well suited for providing 
information about the state of brain tissue, without using more invasive means. Due to the direct 
contact of CSF with the extracellular space of the brain, the biochemical changes in the brain are 
reflected in the CSF (Bouwman et al., 2007a). More specifically, neuropathological processes in 







these byproducts in CSF can provide insight into the cellular changes that are occurring in the 
brain. Specific to AD pathology, there are three primary CSF biomarkers that have been widely 
accepted that include total tau (T-tau), phospho-tau (P-tau), and the 42 amino acid form of β-
amyloid (Aβ42) (Blennow, 2004; Herukka, Hallikainen, Soininen, & Pirttilä, 2005; Jack et al., 
2010). In addition to these well accepted CSF biomarkers for AD, there are a number of other 
biomarker candidates that are currently being explored, although additional evidence is needed to 
support their use. Accumulation of β-amyloid in the brain is believed to occur 10 years or more 
before cognitive symptoms present, and therefore lower levels of Aβ42 in (CSF) prior to 
symptoms of cognitive decline (Buchhave et al., 2012; Jack et al., 2010). 
In addition to reduced levels of Aβ42 in CSF, levels of total tau (T-tau) and of 
phosphorylated tau at threonine 181 (P-tau) have been shown to be elevated in CSF of people 
with AD pathology (Brys et al., 2009; Hampel et al., 2004; Hansson et al., 2006; Herukka et al., 
2005; Mattsson et al., 2009; Riemenschneider et al., 2002). While the presence of Aβ42, occurs 
early in the disease process, tau is detectable in the CFS later than β-amyloid levels. Studies have 
found the Aβ42 levels change early and reach a plateau, while T-tau and P-tau levels in the CSF 
increase slowly over the course of the disease and more correspond with the dementia process 
(Bouwman et al., 2007b; Buchhave et al., 2012; Buchhave et al., 2009; Kanai et al., 1998). Given 
that these two biomarkers show up at different stages of the disease, they each provide unique 
information regarding the stage of the disease process. Where tau is a good indicator of injury to 











 In addition to CSF biomarkers, neuroimaging procedures have been shown to be effective 
biomarkers. Commonly used neuroimaging techniques include structural and magnetic resonance 
imaging (MRI) and positron emission tomography (PET).  These techniques allow for structural, 
functional, and molecular imaging. Structural imaging techniques (i.e. MRI) reflect changes or 
atrophy in the neuroanatomical structure (Frankó, Joly, & Alzheimer’s, 2013; Holland et al., 
2009). These structural changes can be evaluated using qualitative or quantitative techniques. 
Using quantitative techniques involves creating a three-dimensional representation of brain 
structures known to be affected in AD (i.e. hippocampus) is created by tracing the border on 
sequential MRI slices. This allows for quantification of the volumetric and morphometric 
characteristics of the region examined (Hämäläinen et al., 2007; Jack et al., 1997; Karas et al., 
2008). 
While structural techniques are frequently used in clinical settings, as they provide details 
about changes in neuroanatomical structures, they do not allow for direct examination of brain 
functioning. Often presumptions are made regarding the relationships between structure and 
function, however this has been repeatedly shown to be a very complex relationship. Functional 
imaging techniques, such as fMRI, uniquely allow for direct measurement of brain activity. The 
principal outcome measure utilized in fMRI is the blood-oxygenation level-dependent (BOLD) 
signal. BOLD provides a measure of regional brain activity by measuring fluctuations in local 
blood flow and oxygenation. Using this approach, fMRI provides an indication of brain 
physiology and cellular level activation (Mosconi et al., 2010; Protas et al., 2013). To provide 
even more detail about how these changes relate to the Alzheimer’s disease process, task-related 







cognitive tasks affected in AD (i.e. encoding and storage of new memories or sematic language 
tasks) (Binder, Desai, Graves, & Conant, 2009; Koenig et al., 2008). Unfortunately, studies using 
task-related fMRI in AD populations have yielded conflicting results, with some studies finding 
decreased activation (Rémy, Mirrashed, Campbell, & Richter, 2005; Yetkin, Rosenberg, Weiner, 
Purdy, & Cullum, 2006), while others have found higher levels of activation in affected regions 
(Kircher et al., 2007a; O’Brien et al., 2010). The reasons for these seemingly contradictory 
findings are not completely clear, although researchers have posited that disease severity may 
have an impact. Specifically, increased activation is observed in patients who have minimal 
impairments, due to a compensatory mechanism initiated for successful task completion. 
However, brain regions with more advanced atrophy are no longer able perform increased or 
compensatory neuronal activity, resulting in decreased activation, rather than increased, during 
tasks (Kircher et al., 2007b). 
Lastly, using targeted radiotracers, molecular imaging (i.e. PET) measures chemical and 
cellular level changes in the brain. Recently, there has been significant progress in using PET for 
diagnosis and staging of AD and PET has even been proposed for use in staging of preclinical 
AD (Sperling et al., 2011). The advances in this area are due in large part to development and 
identification of new and more well validated radiotracers. Among the well validated amyloid 
radiotracers are, N-methyl-[11C]2-(4′-methylaminophenyl)-6-hydroxybezothiazole or Pittsburgh 
Compound-B (PiB) (Mathis et al., 2003; Matsuda, Shigemoto, & Sato, 2019), flutemetamol 
(Nelissen et al., 2009), florbetapir (Wong et al., 2010), florbetaben (Barthel et al., 2011), and 
[18F]NAV4694 (Seibyl, Barret, Marek, & Reininger, 2013).  
Radiotracers designed to target amyloid alone, are not sufficient for diagnosis of AD. 







the disease progression, as compared to Aβ. Furthermore, PET studies have found there is little 
association between amyloid burden and the severity of cognitive decline (Rabinovici & Jagust, 
2009). Conversely, the relationship between tau pathology and the severity of cognitive decline 
is much closer (Villemagne, Doré, Burnham, Masters, & Rowe, 2018), therefore radiotracers that 
target tau are needed. There have been a number of tau specific radiotracers developed and 
studied including, [18F]Flortaucipir (AV1451) (Schonhaut et al., 2017), [18F]T808(Declercq et 
al., 2016), [18F] THK5117(5317) (Okamura et al., 2013), [18F]THK5351 (Harada et al., 2016), 
[11C] PBB3 (Hashimoto et al., 2015), [18F]PM-PBB3 (Shimada et al., 2018), [18F]GTP1(Sanabria 
Bohórquez et al., 2019), [18F]MK6240 (Betthauser et al., 2019), [18F]PI2620 (Kroth et al., 2019). 
Each of these has strengths and weaknesses, and as a result have not been fully adopted for 
clinical use. Specifically, problems with off-target binding of tau tracers to non-tau protein 
deposits and other molecular structures is common (Leuzy et al., 2019; Okamura et al., 2018). 
The research in this area is rapidly growing and focuses on use of PET for identification of AD 
pathology and responsiveness to treatment. Taken together, PET and the other neuroimaging 
techniques allow for the assessment of changes in brain structures and or processes that have 
been implicated in AD (Menéndez González, 2014).  
Biomarker Neuropsychological Contributions 
Neuropsychological test scores have also been identified as biomarkers. Typically, tests 
that reflect memory and language abilities (Albert, Moss Tanzi, & Jones, 2001; Chapuis et al., 
2016; Ho, & Nation, for the Alzheimer’s Neuroimaging Initiative, 2018) are the strongest 
predictors of AD pathology, although deficits on tests of executive function (Clark et al., 2012; 
Harrington et al., 2013) and visuospatial abilities also have a predictive role (Alladi et al., 2007; 







combination with other biomarkers such as neuroimaging, laboratory tests and genetic studies, 
neuropsychological tests have been shown to contribute significantly to the prediction of AD 
diagnosis above and beyond what is accounted for by these other classes of biomarkers (Ho et 
al., 2018). This suggests a unique role for neuropsychological test scores in early detection 
efforts for AD.  It is also of interest that neuropsychological test scores are useful in predicting 
functioning and ADLs (Ashendorf et al., 2018; de Paula et al., 2015; Jefferson et al., 2006; 
Mlinac and Feng, 2016; Razani et al., 2011) more so than biological or genetic findings, 
underscoring the unique clinical contribution test results have in the treatment of affected 
individuals.  
Early Identification of Alzheimer’s Disease 
 Based on what is known about the neuropathological process underlying AD and that the 
disease process begins as many as 20 - 30 years prior to formal diagnosis (Pengas et al., 2010), 
research has turned towards finding ways of detecting AD in the prodromal phase (Bondi et al., 
2008). This work is predicated on the understanding that early neural dysfunction and associated 
cell death occurs during the period of time prior to onset of clinically significant symptoms. This 
cell death, once occurred, is irreversible and therefore incurable. It is only after this process is 
rather far along that we are currently able to make a diagnosis of AD. The advantages of 
developing early detection techniques, is that this would allow for early intervention and 
potentially the ability to stop or reverse the disease process (Friedrich, 2013; Petersen, Smith, 
Ivnik, Kokmen & Tangalos, 1994). The disadvantages or caution associated with early detection 
is the inherent risk of incorrectly identifying an individual as having AD. In other words, the rate 
of making a false positive error increases when the level of impairment required for 







attempts to identify individuals who will go on to develop AD, either before any cognitive 
changes are present or when mild changes have begun, although do not rise to the level of 
clinical significance. These early detection methods include, neuropsychological testing and the 
biomarkers previously discussed (i.e. CFS, MRI, PET, etc) (Menéndez González, 2014). 
Network Analysis 
A recently developed method of examining the covariance of symptoms has been 
developed called Network Analysis. Network Analysis is a mathematical approach in which 
symptoms are represented as a system and the way those symptoms change in relation to one 
another can be examined (Borsboom & Cramer, 2013). This approach allows the disease to be 
conceptualized not as a collection of symptoms arising from one cause, or as a system, but rather 
something in the middle (Borsboom & Cramer, 2013). Network analysis also allows for the 
identification of symptoms that are highly central. Centrality is a measure of how connected a 
specific symptom is to the other symptoms. Psychological networks are based on the partial 
correlation network that are estimated using regularization techniques. These regularization 
techniques, that allow for the removal of spurious edges, have been developed out of methods 
used in machine learning (Foygel, Mathias, 2010; Meinshausen & Bühlmann, 2006). The 
networks are made up of nodes that are connected to one another by edges. The nodes represent 
observed variables, while the edges represent a statistical relationship between the nodes. In 
recent years, the methodology of network analysis has gained acceptance and has been used 
across the field of psychology, including clinical psychology (Boschloo et al., 2015; Forbush, 
Siew, & Vitevitch, 2016; McNally et al., 2015), psychiatry (Isvoranu, Borsboom, van Os, & 
Guloksuz, 2016; Isvoranu et al., 2017), social psychology (Dalege et al., 2016), and quality of 







that symptoms should be thought of as mutually interactive and reciprocal elements of a complex 
network, rather than symptoms of a disease (Cramer, Waldorp, van der Maas, & Borsboom, 
2010; Schmittmann et al., 2013).  For this reason, the term element is often used rather than the 
more commonly used term symptom. While this distinction is subtle, the use of the word element 
conveys that within these complex networks, the symptoms are thought to be part of a causal 
system (Borsboom, 2008). In other words, changes in one symptom or element may cause 
changes in another. To date, this approach has been used to better understand symptoms and 
psychological disorders, including Major Depressive Disorder, Generalized Anxiety Disorder 
and Schizophrenia (Zamani Esfahlani, Visser, Strauss, & Sayama, 2018). 
Network Analysis has not yet been applied with Alzheimer’s Dementia and the 
associated cognitive symptoms. While there has been substantial research to date on the typical 
pattern and course of decline, there are individuals differences and some individuals present with 
atypical symptoms.  Research using Network Analysis to investigate these differences and if 
there is a systematic pattern has yet to been done. Network Analysis is well suited for 
investigating the relationship between cognitive symptoms and the progression of cognitive 
decline, as it allows for the examining how the symptoms change in relation to one another. This 
would allow for a better understanding of the disease progression, allowing for better treatment 
planning.  
Research Aims and Study Hypotheses 
The aging population and the high prevalence of AD, alongside the exorbitant costs 
associated with this disease, has created a great need to develop a better understanding of the 
course of AD progression. Specifically, how individual differences, such as  impact the 







extensively, there are still many unanswered questions regarding individual differences observed 
in AD. While there has been extensive research into changes that occur in neurocognitive 
functioning, there is also little know about how the cognitive domains change in relation to one 
another as the AD progresses. Based on these needs, the current study was designed with four 
main goals: (1) characterize the network structure of cognitive abilities affected in AD in normal 
aging, (2) characterize the AD symptoms network structure in a clinical sample,  (3) evaluate the 
stability of the network structure, and (4) examine if and how the network structure changes over 
time as the disease progresses. A statistical approach known as Network Analysis was used to 
examine the inter-connectedness of individual cognitive domains with the aim of determining if 
some cognitive domains affected in AD are more central than others. The study also examined 
how the network structure of cognitive domains known to be impacted by AD changes overtime 
in individuals diagnosed with AD. Lastly, the current study aimed to examine the effect of 
individual factors, such as sex on the structure of the network. Understanding if there is a 
particular symptom domain that is more central or if one symptoms domain drives global 
increases in the other domains will contribute to the overall understand of how AD progresses in 
different individuals. This understanding has significant implications to better understanding the 
progression of AD and treatment planning. This will expand upon the current understanding of 
AD course and further aide in treatment planning for individuals with AD. Based on the above 
review of the literature it is hypothesized that: 
1) The overall network structure of cognitive domains affected in AD will differ for those 
individuals with normal cognition as compared to individuals with MCI or Dementia due 







2) The overall network structure of cognitive domains affected in AD will differ for those 
individuals with normal cognition as compared to individuals with MCI or Dementia due 
to AD after diagnosis of MCI or Dementia due to AD is made.  
3) The overall network structure for cognitive domains affected in AD will differ for men 
with MCI or Dementia due to AD as compared to women with MCI or Dementia due to 
AD. 
4) The Temporal Stability of the network will differ for those with normal cognition who 
remain normal over a four year period, from those individuals who are normal at the 








Chapter 3: Methods 
Participants 
 The current study included 864 participants. This included a clinical sample consisting of 
432 individuals with Mild Neurocognitive Impairment (MCI) or Major Neurocognitive 
Impairment (Dementia) due to AD and a healthy control sample of 432 individuals who were 
individually matched to the clinical sample on age, education and sex. Demographic information 
for the groups are presented in Table 1. All participants were selected from the National 
Alzheimer’s Coordinating Center (NACC) Database, which was created in 1999 in the United 
States for the purpose of supporting collaborative research in AD. The NACC is considered one 
of the largest and most comprehensive databases of its type (more detail about the NACC is 
provided in the procedures section). All participants selected from the database for the current 
study were between the ages of 60-90 years old (at the time of their initial evaluation), spoke 
English as a primary language, and did not have significant hearing or vision impairment that 
would interfere with testing procedures. Only individuals with at least four consecutive study 
visits with complete neuropsychological assessment data were included. Study visits were 
typically completed once a year on average.  
Individuals were selected for the clinical sample based on the NACC variable 
NACCUDSD, which indicates the level of cognitive impairment. Individuals were selected if, at 
the time of the initial visit, they did not meet criteria for a cognitive diagnosis and, if by the time 
of the fourth visit, they had been diagnosed (by the study physicians) with either MCI (Mild 
Neurocognitive Disorder; NACCUDSD1=3) or dementia (Major Neurocognitive Disorder; 
                                                
1 The subject’s cognitive status is determined at every visit. Subjects with a clinical diagnosis of normal cognition 







(NACCUDSD2=4) due to probable AD (NACCALZD3=1). The criteria used for determining 
probably AD for the NACCALZD variable has changed from the UDSD 1.0 and 2.0 to the 
UDSD 3.0. For the UDSD 1.0 and 2.0 the  National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders 
Association (NINCDS-ADRDA Alzheimer's Criteria; now known as the Alzheimer's 
Association). This criteria was then changed for the UDSD 3.0 and the National Institute on 
Aging and Alzheimer’s Association (NIA-AA) criteria is now used. 
  We refer to this sample as the Converter group because they converted to a diagnosis 
over the course of the study evaluations. Participants were excluded from the Converter group if 
they had a history of traumatic brain injury or another neurological disorder (e.g., seizure 
disorder). Additional exclusion criteria included: 1) current or past medical condition or 
neurological condition known to significantly affect the central nervous system 2) or were taking 
                                                                                                                                                       
diagnosis of dementia have naccudsd = 4. Subjects who are cognitively impaired but who do not meet the criteria 
for MCI have naccudsd = 2. 
 
2 The subject’s cognitive status is determined at every visit. Subjects with a clinical diagnosis of normal cognition 
have naccudsd = 1. Subjects with either amnestic or non-amnestic MCI have naccudsd = 3 and those with a 
diagnosis of dementia have naccudsd = 4. Subjects who are cognitively impaired but who do not meet the criteria 
for MCI have naccudsd = 2. 
 
3 Subjects with normal cognition have naccalzd = 8. Subjects with any cognitive impairment (dementia, MCI, or 
impaired, not MCI) and Alzheimer’s disease indicated as the etiologic diagnosis have naccalzd=1. Subjects with 
cognitive impairment and no Alzheimer’s disease etiologic diagnosis have naccalzd=0. To determine whether 
the subject was cognitively impaired, not MCI, or had MCI or dementia, refer to the naccudsd variable. It is 
important to note that the criteria for an etiologic diagnosis of Alzheimer’s disease is different in versions 1-2 and 
3: in v1.2 and v2, the NINCDS/ADRDA criteria were applied and in v3 the NIA-AA criteria for AD dementia are 








medication at the time of the evaluation that may affect central nervous system function, with the 
exception of medication that is specified for the treatment of dementia and its symptoms and 3) 
diagnosis of substance abuse or dependence at any of the data collection time points. Of the over 
38,000 subjects in the database, 433 individuals were selected, based on the above process. One 
of these individuals was excluded because five years had elapsed between the first and second 
assessment time point, resulting in a final Converter group of 432 participants. The demographic 
characteristics of the dataset are included in Table 1.  
Individuals in the Control group were selected if they did not at any time over the course 
of the selection period (initial visit through fourth visit) meet criteria for cognitive impairment 
(i.e. clinical diagnosis of normal cognition; NACCUDSD1=1). Participants were excluded if they 
had a history of traumatic brain injury or another neurological disorder (e.g., seizure disorder). 
Additional exclusion criteria included: 1) current or past medical condition or neurological 
condition known to significantly affect the central nervous system 2) or were taking medication 
at the time of the evaluation that may affect central nervous system function 3) diagnosis of 
substance abuse or dependence at any data collection time point.  
The Control group was selected by individually matching participants to those in the 
clinical group on the three key demographic variables of sex, age, and education at the first 
evaluation. These variables were selected because of differences between men and women 
reported in the AD literature and because of the well documented strong associations between 
age and education with neurocognition. Since it was often the case that there were multiple 
individuals in the dataset who could be matched to a clinical sample participant on sex, age, and 
education, random selection was used to determine with individual was ultimately included in 







possible match was selected. For example, if there was no control in the data set that could be 
matched to a Converter group participant who was 80-year-old, male, with 21 years of education, 
then a control was selected who was 80 years old, male, with 20 years of education. In this case, 
education was the non-matching variable and the decision to select an individual with more or 
less education was determined by a “coin flip” selection technique. If there were multiple 
individuals who had 20 years of education instead of 21, then random selection was used to 
determine which individual would be included in the Control group. Details of selection process 
















Excluded (n = 1,855) 
¨  Endorsed exclusion criteria (n = 1,023) 
¨  Missing neurocognitive data (Subjects missing 
individual subtest scores were excluded)  (n = 832) 
Case-control study used to select Control 
Group (remains cognitively normal across all 
four time points, and matched to Converter 
Group on Sex, Age, and Education (n = 432) 
Excluded (n =31,127) 
¨   Not cognitively normal at time 1 (n = 9,301) 
¨   Less than 4 consecutive assessment (n = 20,839) 
¨   Outside of age range (n = 987) 
Converter Group (Develop MCI or 
Dementia due to AD by time 4) 
 (n = 432) 
Subjects eligible for either Control or Converter groups (n = 7,709) 
 Total subjects in the NACCUDS  
(n = 38,836) 
Subject available for selection (n = 5,854) 
Total sample selected using Case-
control Study design (n = 864) 
Control Group (n = 432) 







Table 1. Demographic and Clinical Characteristics of the Sample. 
 
Variable Control Converter 
 Mean SD Mean SD 
Education (time 1) 15.7 2.8 15.7 2.9 
Age (time 1) 76.4 7.0 76.4 7.0 
 N N 
Sex   
   Male 180 180 
   Female 252 252 
Race   
   Caucasian 371 360 
   African American 51 65 
   American Indian 1 0 
   Pacific Islander 0 0 
   Asian 8 5 
   Other 1 2 
Handedness   
   Left 27 29 
   Right 388 388 
   Ambidextrous 17 11 
   Unknown 0 4 
Cognitive Diagnosis at Assessment 4 
   No Cognitive Diagnosis 432 0 
    MCI/Mild NCD 0 355 





Participants were evaluated using neuropsychological measures of cognitive functioning, 
including measures sensitive to cognitive decline associated with AD (Ivnik et al., 1992b; Ivnik, 
Malec, Tangalos, Petersen, & et, 1990; Ivnik et al., 1992c; Ivnik et al., 1992a; Ivnik et al., 1992c; 
Lucas et al., 1998; Petersen, Smith, Kokmen, Ivnik, & Tangalos, 1992; Petersen, Smith, Ivnik, 
Kokmen, & Tangalos, 1994; Steinberg, Bieliauskas, Smith, Ivnik, & Malec, 2005; Steinberg, 







included brief measures of attention, processing speed, executive function, episodic memory, and 
language. The battery used has been changed over the course of the NACC project to update the 
battery based on advances in test development, so some of the cognitive measures have been 
changed over the years. The reasons for these substitutions are discussed below. Research has 
been done to equate the measures used in the different versions of the UDS (UDSNB 1.0, 
UDSNB 2.0, and UDSNB 3.0) and conversion tables are available to equate scores from the 
various tests. Tables available on the NACC website allow researchers to convert scores from 
UDSNB 1.0 and UDSNB 2.0 to the measures used on UDSNB 3.0, allowing for direct 
comparisons in the event subjects selected received the updated battery. The tests used for the 
UDSNB 1.0 and UDSNB 2.0 included the MMSE, Logical Memory IA- Immediate and 
Delayed, digit span test forward and backward, category fluency and letter fluency, Boston 
Naming, and the trail making test (A and B) (Weintraub et al., 2009). The UDSNB 1.0 and 
UDSNB 2.0 battery consisted of the same tests, with the only differences being clarification of 
instructions for administration and scoring, and one modification to the instructions of the 
delayed story recall (Logical Memory A Delayed). 
After several years, limitations of the battery were identified and a work group was 
created to address these limitations. The first limitation of the battery was that healthy controls 
showed practice effects on longitudinal follow-up, particularly on measures of memory. Second, 
the UDSNB 1.0 and 2.0 used published tests. Use of published tests increased the likelihood of 
multiple exposures to the test content, both through clinical practice or through participation in 
research conducted at the ADCs. Additionally, use of published tests involves licensing costs and 
restrictions on sharing the materials. Third, early detection requires tests that are sensitive to the 







that measure visuospatial functions and nonverbal memory, which has now been shown to be 
affected in some cases of AD (Alladi et al., 2007; Hof, Vogt, Bouras, & Morrison, 1997; 
Mendez, Ghajarania, & Perryman, 2002;). Furthermore, visuospatial symptoms have been shown 
to arise later in AD, and the pattern of performance differs on these visuospatial construction and 
memory tasks between individuals with frontal and parietal cortical atrophy (Possin, Laluz, 
Alcantar, Miller, & Kramer, 2011a).  
  The work group was tasked to select tests that would be comparable in many ways to the 
previous version of the USDNB, while addressing these limitations. The following battery 
selected to accomplish these goals included the following tests: 1) the Montreal-Cognitive 
Assessment (MoCA), which replaced the The Mini-Mental State Examination  (MMSE); 2) the 
Craft Story 21 Recall Immediate and Delayed, which replaced the WMS Logical Memory; 3) the 
Benson Complex Figure Copy Immediate and Delayed which was new to the battery; 4) the 
Number Span Test forward and backward which replaced forward and backward Digit Span; 5) 
the Trail Making test (A and B) which was retained from UDSNB 1.0 and 2.0; 6) the 
Multilingual Naming Test (MINT), which replaced the Boston Naming Test; 7) and Category 
Fluency (Animal and Vegetable) which was retained from UDSNB 1.0 and 2.0.   
 Once the UDSNB 3.0 battery was created, research  was conducted to establish the 
equivalence of the new tests to the previously used measures and develop tables that allow 
researchers using the NACC database to calculate an equivalence score for the tests on the 
UDSNB 1.0 and 2.0 to scores on the UDSNB 3.0 (Monsell et al., 2016). These conversions allow 
for direct comparison of test scores from the different iterations of the UDSNB, making 
longitudinal comparisons possible. Tables are also available to produce standardized scores 







study, most participants were administered UDSNB 1.0 or 2.0, so for those who completed 
UDSNB 3.0, raw scores were converted using the conversion tables provided on the NACC 
website (https://www.alz.washington.edu/ WEB/npsych_means.html) so they would be 
equivalent across UDSNB versions. Demographic corrections were not used in the current study 
because the control and Converter groups were matched on sex, age, and education. Raw scores 
were standardized using the mean and standard deviation of the current sample (N=864) This 
conversion procedure is discussed in the Analysis section. Below is a description of each 
measure used in the UDSNB versions.  
Cognitive Screener 
 The Mini-Mental State Examination  (MMSE; Folstein, Robins, & Helzer, 1983) and the 
Montreal-Cognitive Assessment (MoCA; Nasreddine et al., 2005) are cognitive screeners that 
aim to provide a snap shot of cognitive functioning. These screeners are not particularly sensitive 
to signs of early dementia, particularly when the individual has above average (or higher) 
cognitive abilities (Tombaugh & McIntyre, 1992). These cognitive screeners are however useful 
for identifying dementia when it is present and distinguishing between mild, moderate and severe 
stages of dementia (Galasko, Gould, Abramson, & Salmon, 2000). Based on this, MMSE and 
then eventually the MoCA were selected to aid in staging clinical milestones once dementia is 
diagnosed. 
Episodic Memory  
 Logical Memory IA- Immediate and Delayed (Wechsler, 1987b) from the WMS-R and 
Craft Story 21 Recall Immediate, and delayed are measures of auditory verbal learning and 







asked to recount the story after a delay of 20-30 minutes. The use of a delay allows for 
assessment of encoding, storage, and recall of structured verbal memory.  
Visuospatial Construction and Memory  
The Benson Complex Figure Copy Immediate and delayed is a measure of the ability to 
perceive and construct visual stimuli (copy) and to then recall that information after a delay 
(Possin, Laluz, Alcantar, Miller, & Kramer, 2011b; Possin, 2010). Constructional abilities (Copy 
condition) are assessed by evaluating the presence and placement of figural elements. Then after 
a delay, visual memory is assess by asking the participant to reproduce the figure from memory. 
Once again, the figure is score based on the presence and placement of figural elements. 
Unfortunately, this measure was not available for most participants in the current study because 
it was not added until UDSNB 3.0, so we did not include this measure in our analyses.  
Simple Attention and Working Memory 
Digit Span test from the WMS-R (Wechsler, 1987b) or the Number span test forward and 
backward were used to measure simple attention and working memory.  Digit Span test from the 
WMS-R was administered in its standard format, which included scores for total trials and the 
longest correctly recited digit sequence. The UDSNB 3.0 uses the Number span test forward and 
backward, instead of the WMS-R Digit Span. The Number span test helps to reduce practice 
effects, by using randomly generated number series. The number span score is based on the 
longest list recalled. 
Verbal Fluency 
Both semantic and phonemic fluency are measured. Word fluency is measured by asking 
participants to generate a list of words based on a provided semantic category. Scores are based 







by errors, note is made of errors and rule violations. UDSNB 1.0 and 2.0 included one semantic 
category (animals), and a second category (vegetables) was added for the UDSNB 3.0). For 
phonemic fluency or letter fluency participants are asked to generate words that start with a 
given letter. Again, scores are based on the number of correct words generate in 60 seconds and 
note is made of errors and rule violations. Phonemic fluency was not included in the UDSNB 
2.0, although was added to the UDSNB 3.0. A letter generation tasks was added (“F” and “L”) 
for UDSNB 3.0. Unfortunately, this measure was not added until the UDSNB 3.0 and the 
majority of the subjects of the current study received the UDSNB 1.0 and 2.0, which did not 
include a measure of phonemic fluency. 
Confrontation Naming 
 The Boston Naming Test (BNT) was used in the UDSNB 1.0 and 2.0 (Kaplan, Goodglass, 
& Weintraub, 1983), while the MINT (Multilingual Naming Test) (Gollan, Runnqvist, Montoya, 
Cera, 2012; Ivanova, Salmon, & Gollan, 2013) replaced the BNT for the UDSNB 3.0. The BNT 
and the MINT were used to test confrontation naming, a measure of semantic language skills. 
Participants are asked to name simple line drawing of objects that are individually presented for 
20 seconds. In an attempt to save time, a short version of the BNT (the 30-odd numbered items) 
was constructed. The administration of this short version BNT adheres to the standard full BNT 
in all ways, aside from the 6 consecutive failures discontinue rule. The score consists of the total 
number of line drawings that are named correctly, plus the number of items named correctly with 
a semantic cue. The MINT consists of 32 items, and was developed to be used with individuals 
who are multilingual or monolingual in several languages including English, Spanish, Hebrew, 







monolingual English speakers and was not designed to asses naming skills in monolinguals of 
other languages or multilinguals.  
Processing Speed  
 The trail making tests were retained from the UDSNB 2.0 to measure processing speed 
(part A) and executive function (part B) (Reitan & Wolfson, 1993). Part A of the Trail making 
test requires the participants to draw a line connecting numbers in sequence, as quickly as 
possible. Trail making test part A is used to measure processing speed, and is scored by 
recording the time it takes the participant to complete the task. Errors are corrected in real time, 
and as a result, when errors are committed, the completion time is inherently prolonged, resulting 
in a lower score, i.e., increased time to complete the test. Additionally, the number and type of 
errors are recorded, but are not used as a separate score to judge performance (Reitan & 
Wolfson, 1995). The UDSNB 1.0 and 2.0 also included the Digit Symbol Coding from the 
WAIS-R as an additional measure of processing speed. Digit Symbol Coding was administered 
in accordance with the instructions contained in the WAIS-R administration manual and scored 
by totaling the number of items completed correctly in 90 seconds (Wechsler, 1987a). This test 
was removed from the UDSNB for the 3rd version and not substituted or replaced with another 
measure of processing speed. As a result, the WAIS-R was not included in the current study, due 
to high levels of missing data at assessment time point 4, with no alternative test available for 
substitution.  
Executive Functioning 
 Part B of the Trail Making Test is a more complex task that requires set shifting, an 
aspect of executive functioning. In part B, participants much sequence both numbers and letters, 







1995). Scoring and administration procedures are similar to those described for Trail Making 
Test part A.  
Procedures 
NACC Database 
The National Alzheimer’s Coordinating Center (NACC) database was created in 1999 in 
the United States for the purpose of supporting collaborative research in AD and is considered 
one of the largest and most comprehensive databases of its type. There have been several 
iterations of the database since its creation, but in its most recent form, the Uniform Data Set 
(UDS) was implemented in 2005 as a way of collecting standardized, longitudinal data on 
individuals with AD and other degenerative diseases. The newest version of the UDS 3.0 
(version 3) was implemented in March of 2015 and includes prospective and longitudinal clinical 
data for over 39,400 subjects (as of December 2018). The data is available to both Alzheimer’s 
Disease Center (ADC) and non-ADC researchers and has resulted in more than 600 publications 
to date (as of December 2018). The dataset also includes neuropathology data for more than 
16,600 subjects, which contains autopsy data for 5,500 subjects that had been followed 
longitudinally in the UDS. The NACC UDS is able to offer such a large sample size due to the 
collaboration between centers. However, each center determines the methods used to enroll 
subjects. Some common ways in which subjects come  to be involved include clinician referral, 
self-referral by patients or family members, active recruitment through community organizations, 
and volunteers who wish to contribute to research on various types of dementia. Volunteers, with 
normal cognition, are also enrolled at most centers and these individuals tend to be highly 
educated. As a result, NACC subjects are not a statistically based sample of the U.S. population 







determinations regarding prevalence or incidence of AD. Instead, they are considered a referral-
based or volunteer case series. By whichever means the subjects come to the study, they are 
enrolled on a volunteer basis and written informed consent is obtained from all participants and 
their co-participant (usually a spouse, close friend or family member who provides informant or 
collateral reporting on the status of the participant). The cognitive status of participants ranges 
from normal to demented and may change over the course of their participation in the study.  
The UDS dataset of the NACC database consists of longitudinal data that is collected 
annually (on average) using a standardized evaluation for subjects enrolled in the ADC. Data is 
collected from subjects and their co-participants by trained clinicians and/or clinic personnel. 
Diagnoses are made one of two ways, either by a consensus team or by the physician who 
conducted the examination. The primary focus of the ADC’s is Alzheimer's disease, however, 
data collection includes a variety of other degenerative disorders, such as vascular dementia, 
Lewy body dementia, and frontotemporal lobar degeneration. Data is collected during in-person 
office visits for some tests like the neuropsychological tests, but home visits and telephone calls 
are also used for collection of other data. Subject death and drop-out are documented using 
milestone forms. The topics included in the Uniform Data Set include socio-demographics on 
subject and co-participant, family history, dementia history, neurological exam findings, 
functional status, neuropsychological test results, clinical diagnosis, neuroimaging when 
available, and APOE genotyping. 
Database 
Participants were selected for the current study from the NACC database based on 
specific inclusion and exclusion criteria previously described. Once selection criteria were 







received different versions of the UDSND over the course of their participation in the study (i.e. 
visits 1, 2, and 3 they received UDSND 2.0 and visit 4 they received UDSNB 3.0). In these 
cases, the NACC conversion tables were used to convert the scores of the UDSNB 3.0 to be 
comparable to the UDSNB 2.0 (Monsell et al., 2016). Once this process was completed, cases 
with incomplete data were removed. Raw scores were then transformed to standardized scores 
(z-scores) using the means and standard deviation at each time point for the entire sample 
(controls and converters). The z-score means and standard deviations for both groups on each 
test and at each time point are presented in Table 2 and Table 3. The raw scores means and 
standard deviations for both groups on each test and at each time point also presented in Table 4 









Table 2. Z-score overall mean and standard deviations (SD) at each time point of the 9 cognitive 
domains included in the network analysis for Both Control and Converter Group.  
Variable Time 1 Time 2 Time 3 Time 4 Time C 
 Mean  SD Mean  SD Mean  SD Mean  SD Mean  SD 
MMSE - Control 0.25 0.77 0.16 0.87 0.13 0.89 0.16 0.93 0.14 0.89 
MMSE- Converter -0.27 1.12 -0.31 1.13 -0.84 1.15 -0.84 1.15 -0.56 1.16 
LMI - Controls 0.06 0.97 0.13 0.95 0.26 0.98 0.35 1.01 0.26 0.96 
LMI - Converter -0.27 0.97 -0.59 1.07 -0.69 1.11 -0.69 1.11 -0.82 1.12 
LMII- Controls 0.13 0.93 0.21 0.92 0.33 0.99 0.44 1.02 0.33 0.99 
LMII - Converter -0.34 0.96 -0.39 0.99 -1.06 0.93 -1.06 0.93 -0.73 0.98 
DF- Controls 0.10 0.94 0.09 0.91 0.18 0.92 0.11 0.91 0.14 0.89 
DF - Converter -0.09 1.01 -0.08 1.03 -0.69 1.01 -0.69 1.01 -0.29 1.04 
DB- Controls 0.13 0.97 0.12 1.01 0.17 0.99 0.24 0.97 0.21 0.98 
DB - Converter -0.16 0.99 -0.14 0.96 -0.78 0.94 -0.78 0.94 -0.39 0.99 
Cat Fluency- Controls 0.23 1.16 0.32 1.19 0.24 1.20 0.21 1.19 0.26 1.09 
Cat Fluency - Converter -0.26 0.92 -0.80 1.60 -0.80 0.84 -0.80 0.84 -0.72 1.11 
Trails A- Controls 0.17 0.94 0.27 0.86 0.35 0.84 0.28 0.96 0.27 0.94 
Trails A - Converter 0.14 1.09 0.18 1.12 0.85 1.14 0.85 1.14 0.39 1.20 
Trails B- Controls 0.19 0.90 0.26 0.93 0.30 0.84 0.27 1.01 0.28 0.93 
Trails B - Converter 0.20 1.08 0.24 1.08 1.02 1.14 1.02 1.14 0.59 1.24 
Boston Naming- Controls 0.20 0.88 0.30 0.87 0.34 0.91 0.31 0.97 0.31 0.92 








Table 3. Raw Score overall mean and standard deviations (SD) at each time point of the 9 
cognitive domains included in the network analysis for Control Group.  
Variable Time 1 Time 2 Time 3 Time 4 Time C 
 Mean SD Mean SD Mean SD Mean SD Mean SD 
MMSE - Control 29.24 1.03 29.09 1.16 29.02 1.19 29.03 1.25 29.03 1.18 
MMSE- Converter 28.51 1.48 28.09 1.83 27.74 2.10 27.25 2.40 27.60 2.02 
LMI - Controls 14.02 3.79 14.25 3.74 14.70 3.87 15.04 3.96 14.71 3.78 
LMI - Converter 11.88 3.86 11.44 4.17 10.98 4.32 10.30 4.59 10.50 4.37 
LMII- Controls 12.97 3.95 13.34 3.93 13.85 4.27 14.28 4.36 13.84 4.22 
LMII - Converter 10.10 4.10 9.71 4.57 9.06 4.74 8.25 5.10 8.55 4.74 
DF- Controls 8.73 1.95 8.69 1.88 8.85 1.89 8.68 1.86 8.76 1.84 
DF - Converter 8.38 1.98 8.38 1.99 8.15 1.99 8.10 1.99 8.17 1.98 
DB- Controls 7.09 2.12 7.04 2.21 7.11 2.16 7.25 2.13 7.20 2.14 
DB - Converter 6.41 2.13 6.42 2.09 6.19 2.00 6.04 2.03 6.16 2.02 
Cat Fluency- Controls 17.54 4.30 17.81 4.39 17.58 4.51 17.45 4.29 17.54 4.06 
Cat Fluency - Converter 15.48 3.91 14.88 3.96 14.26 3.75 13.41 3.79 13.95 3.67 
Trails A- Controls 34.33 13.94 33.53 12.89 33.02 12.75 34.63 14.91 34.26 14.34 
Trails A - Converter 38.89 17.29 39.21 17.48 41.02 19.03 43.46 23.25 41.14 19.09 
Trails B- Controls 87.86 43.49 86.63 45.23 86.74 41.84 89.82 49.24 88.06 45.89 
Trails B - Converter 107.71 53.40 112.62 57.80 126.93 69.37 141.34 79.47 132.04 71.85 
Boston Naming- Controls 27.60 2.83 27.86 2.79 27.90 2.95 27.77 3.13 27.79 2.97 




The cognitive domains were represented by the neurocognitve test scores known to assess 
specific cognitive domains affected by Alzheimer’s Disease. Cross sectional analyses were 
conducted to examine the network structures of neurocognitve test scores for both the healthy 







normal. In other words, before the clinical group met criteria for a cognitive diagnosis. The 
networks were then estimated at each time point (Time 1- Time 4) as well as the time point at 
which the members of the Converter group first met criteria for a cognitive diagnosis (i.e. MCI 
or Dementia). Finally, the Converter group was subdivided by sex and the networks for men and 
women were estimated.  
Network Estimation 
Network analyses of the cognitive domains affected by AD were conducted using the R-
Package qgraph in Rstudio. Qgraph allows for the estimation and visualization of the networks 
examined. Gaussian Graphical Model (GGM) was used to estimate the regularized partial 
correlation networks for each group at each time point. The graphical lasso (GLASSO) algorithm 
was used to control for spurious correlations, which can occur with multiple testing (Friedman 
Hastie, & Tibshirani, 2008). This procedure produces a sparse network structure with nodes 
connected by edges that represent conditional dependence relations. In other words, the edges 
between nodes represent the nodes that remain associated, after controlling for all other nodes in 
the network. The results of these procedures are visualized as a graph with nodes connected by 
edges. The edges are shown in green if the association between nodes is positive and red if the 
associations between nodes are negative. The overall strength of each network was used to 
calculate the Global Strength of the network. The global strength is the sum of the absolute value 
of all edges in the network (van Borkulo et al., 2015).  
The following networks analyses were performed for the converter and Control groups: 
1) Networks were estimated for the initial assessment (Time 1) for both the converters and the 
Control groups; 2) The networks for each of the four time points were also estimated to examine 







individuals in the Converter group first met criteria for a cognitive diagnosis (MCI or Dementia). 
Because each participant in the Converter group was demographically matched to a participant in 
the Control group, the corresponding time point for the matched control participant was also 
selected and the network was estimated for this matched group of controls. In other words, if an 
individual in the Converter group met criteria for MCI at time 3, then assessment results for their 
matched control at time point 3 were included in the Control group database for this network 
analysis.  
In addition to comparing the converter and Control groups, the individuals in the 
Converter group were subdivided by sex and the networks were estimated for men and women at 
each time point (Time 1- Time 4 and Time C). Thus, a total of 5 networks analyses were 
performed for the men from the Converter group and 5 networks analyses were performed for 
the women from the Converter group that included: 1) Networks were estimated for the initial 
assessment (Time 1) for both the men from the Converter group and the women from the 
Converter group; 2) Networks were estimated for each follow-up time point (Time 2- Time 4) 
for both the men from the Converter group and the women from the Converter group; and 3) The 
network time at which the participants first met criteria for a cognitive diagnosis was also 
estimated for both the men from the Converter group and the women from the Converter group.  
Network Inference 
To provide more insight into the impact of items on the network structures, several 
centrality analyses were performed. Based on the methods used by previous studies employing 
Network Analysis, the centrality indices calculated included, strength, betweenness, closeness, 
and expected influence (Opsahl, Agneessens, & Skvoretz, 2010; Robinaugh, Millner, & 







node’s relative strength and indicates which of the nodes has the strongest connections with all 
other nodes. This is calculated by summing the absolute values of all of the edge weights that are 
connected to the node in question. Betweenness indicates the frequency of a node being on the 
shortest path between all pairs of nodes in a network. Closeness is a measure of the average 
length between all other nodes. Closeness is calculated by summing the inverse of the distance 
between one node and all other nodes. Very commonly, researchers use only these three 
centrality indices when examining their networks, however strength, betweenness, and closeness 
do not distinguish between positive and negative edges, and therefore may not adequately 
account for the nature and strength of the influence a specific node has within the network. For 
this reason, we chose to include the less commonly used measure of expected influence. 
Expected influence provides information about the nature and strength of the node’s cumulative 
influence within the network, taking into account positive and negative relationships. This 
provides insight into the role each node is expected to play in the activation, persistence, and 
remission of the network (Robinaugh et al., 2016). 
Next, analyses were performed to estimate the accuracy of the centrality indices. The R 
package bootnet was used for this process. Bootnet utilizes a case-dropping subset bootstrapping 
approach that outputs the number of participants from the dataset or cases that could potentially 
be dropped from the dataset before causing the network to become unstable. Bootnet also 
estimates the correlation stability coefficient which ranges from 0-1. Values of 0.25 - .49 indicate 
moderate stability, while values above 0.5 indicate strong stability. We then used bootnet to 
estimate the accuracy of edge-weights. This is done by calculating bootstrapped 95% confidence 
intervals (CIs) around each of edge weights. Smaller CIs indicate the estimation of the edges is 







centrality indices. Each time drawing 1000 bootstraps. It is important to consider, however, that 
the edge weights difference test and centrality difference test do not control for multiple testing. 
To date, there is unfortunately no method available for examining these aspects of the network 
that does control for multiple testing.   
Network Comparison Test 
 To date, a method for comparing the stability of more than two networks is not available. 
As a result, comparisons were performed to assess the difference in stability of the network 
structures between the groups at different stages of the disease process. Converters and Controls 
were compared at times 1, 2, 3, 4, and C. Also, men from the Converter group were compared to 
women from the Converter group at times 1, 2, 3, 4, and C. The temporal stability of the network 
structures of the Converters group was assessed by comparing each time point to all other time-
points (i.e. Converters time 1 vs. Converters time 2, and Converters time 1 vs. Converters time 3, 
etc.). To make these comparisons the R package NetworkComparisonTest was used (van 
Borkulo, 2016; van Borkulo et al., 2017). Specifically, the global strength invariance test was 
used, which assess if the overall level of connectivity is equal across networks. The overall 
connectivity is the weighted absolute sum of all edges in the network (Opsahl et al., 2010). The 
results of the network comparison tests are presented as a p-value, with alpha level of < 0.05 
indicating significant difference in global strength invariance between the networks (van Borkulo 
et al., 2017). When the global strength invariance test is significant, it suggests that the networks 
being compared are different from each other. We also calculated maximum difference in edge 
weights which is a measure of difference in the overall structure of the networks. Finally, a 
Centrality Difference Test was performed. Centrality Difference Test was performed to evaluate 







Chapter 4: Results 
Network Structure 
The control and Converter group estimated networks for the 9 cognitive tests are 
presented in Figures 1 - 10. Figures 1 – 4 represent the estimated networks for the Control group 
at each time point (Time 1-4). Figure 5 represents the estimated network for Control group 
participants who were selected to match the Converter group at Time C (the time point at which 
each converter first met criteria for a cognitive diagnosis of either MCI or Dementia due to 
Alzheimer’s disease). Figures 6 – 9 represent the estimated networks for the Converter group at 
each time point and Figure 10 presents the network for the time point at which each participant 
in the Converter group first met criteria for a cognitive diagnosis of either MCI or Dementia due 
to Alzheimer’s disease.  
As can be seen from the Figures 1 – 10, across all the time points both the Control and 
Converter groups evidence strong positive connections (an edge weight > 0.4, is "Strong",  > 0.1 
is "Moderate", and < 0.1 is "Weak") between Logical Memory I (LOG) and Logical Memory II 
(MEM) at all time points (Controls: T1 = 0.80, T2 = 0.82, T3 = 0.83, T4 = 0.83, TC = 0.81; 
Converter: T1 = 0.78, T2 = 0.80, T3 = 0.84, T4 = 0.81, TC = 0.76). There were also strong 
positive connections between Trails A and Trails B, both the Control and Converter groups, at all 
time points (Controls: T1 = 0.47, T2 = 0.47, T3 = 0.56, T4 = 0.43, TC = 0.43; Converter: T1 = 
0.54, T2 = 0.51, T3 = 0.53, T4 = 0.46, TC = 0.49). At several time points, strong positive 
connections were present between Digits Span Forward (DIGIF) and Digits Span Backward 








Figure 2. Network Analysis for Controls Time 1 
 
Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, 
DIGIB = Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = 
Mini Mental Status Exam, TRAILA = Trails A, TRAILB = Trails B 
 
 
Figure 3. Network Analysis for Controls Time 2 
 
Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, 
DIGIB = Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = 














Figure 4. Network Analysis for Controls Time 3 
 
Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, 
DIGIB = Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = 
Mini Mental Status Exam, TRAILA = Trails A, TRAILB = Trails B 
 
 
Figure 5. Network Analysis for Controls Time 4 
 
Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, 
DIGIB = Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = 














Figure 6. Network Analysis for Controls at the Time of Conversion to MCI or Dementia for 
matched converters. 
 
Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, 
DIGIB = Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = 
Mini Mental Status Exam, TRAILA = Trails A, TRAILB = Trails B 
 
 
Figure 7. Network Analysis for Converters Time 1 
 
Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, 
DIGIB = Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = 











Figure 8. Network Analysis for Converters Time 2 
 
Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, 
DIGIB = Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = 
Mini Mental Status Exam, TRAILA = Trails A, TRAILB = Trails B 
 
 
Figure 9. Network Analysis for Converters Time 3 
 
Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, 
DIGIB = Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = 













Figure 10. Network Analysis for Converters Time 4 
 
Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, 
DIGIB = Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = 
Mini Mental Status Exam, TRAILA = Trails A, TRAILB = Trails B 
 
 
Figure 11. Network Analysis for Converters at the Time of Conversion to MCI or Dementia. 
  
Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, 
DIGIB = Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = 










Figures 11 – 20 present the estimated networks for the Converter group when subdivided 
into male and female groups. Figures 11 – 15 are for males and 16 – 20 are for females. When 
the Converter group was subdivided by sex, similar trends were observed. For both men and 
women, there were strong positive connections between Logical Memory I (LOG) and Logical 
Memory II (MEM) at all time points (Men: T1 = 0.75, T2 = 0.78, T3 = 0.82, T4 = 0.78, TC = 
0.76; Women: T1 = 0.80, T2 = 0.80, T3 = 0.82, T4 = 0.77, TC = 0.73). There are also strong 
positive connections between Trails A and Trails B, groups from the Converter group, at all time 
points (Men: T1 = 0.53, T2 = 0.58, T3 = 0.53, T4 = 0.46, TC = 0.47; Women: T1 = 0.52, T2 = 
0.43, T3 = 0.53, T4 = 0.43, TC = 0.48). Strong positive connections were also present between 
Digits Span Forward (DIGIF) and Digits Span Backward (DIGIB) at several time points (Men: 
T3 = 0.42; Women: T1 = 0.42, T4 = 0.42, T = 0.40).  
 
 
Figure 12. Network Analysis for Men in the Converters Group at the Time 1 
 
Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, 
DIGIB = Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = 








Figure 13. Network Analysis for Men in the Converters Group at the Time 2 
 
 
Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, 
DIGIB = Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = 
Mini Mental Status Exam, TRAILA = Trails A, TRAILB = Trails B 
 
 
Figure 14.  Network Analysis for Men in the Converters Group at the Time 3 
 
Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, 
DIGIB = Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = 










Figure 15. Network Analysis for Men in the Converters Group at the Time 4 
 
Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, 
DIGIB = Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = 
Mini Mental Status Exam, TRAILA = Trails A, TRAILB = Trails B 
 
 
Figure 16. . Network Analysis for Men in the Converters Group at the Time of conversion to MCI 
or Dementia (Time C). 
 
Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, 
DIGIB = Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = 







Figure 17. Network Analysis for Women in the Converters Group at the Time 1
 
Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, 
DIGIB = Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = 
Mini Mental Status Exam, TRAILA = Trails A, TRAILB = Trails B 
 
 




Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, 
DIGIB = Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = 












Figure 19. Network Analysis for Women in the Converters Group at the Time 3 
 
 
Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, 
DIGIB = Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = 
Mini Mental Status Exam, TRAILA = Trails A, TRAILB = Trails B 
 
 




Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, 
DIGIB = Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = 









Figure 21. Network Analysis for Women in the Converters Group at the time of conversion to 




Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, 
DIGIB = Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = 




Accuracy of the networks was then examine using bootstrapping and the results of these 
analyses are presented in Figures 21 - 25.  Figure 21 contains boot strapping results the 
correspond to network estimations presented in Figures 1 – 4. Figure 22 contains boot strapping 
results the correspond to network estimations presented in Figures 6 – 9. Figure 23 contains boot 
strapping results the correspond to network estimations presented in Figures 11 – 14. Figure 24 
contains boot strapping results the correspond to network estimations presented in Figures 15 – 
19. Figure 25 contains boot strapping results the correspond to network estimations at the time 
point C (Figures 5, 10, 15, and 20).  In these figures, the sample edge-weights of each edge are 
indicated with a solid red line, bootstrapped values are indicated by a solid black line, and the 







the X axis represents sample edge weight value of each edge in the network and the y Axis 
represents each edge in the network (e.g., the first edge listed is the edge between the 
DIGIFZSCORE and CATFLUENCYZSCORE nodes). Edges are listed in order of edgeweight 
from lowest to highest. While there is some variability in confidence intervals around the nodes, 
the bootstrapping results support the accuracy of the networks.  As can be seen from the Figure, 
the gray bars indicate narrow confidence intervals around most nodes. The accuracy of these 
networks was supported by the bootstrapping graphs shown in Figure 21 – Figure 25.  
 
 
Figure 22. Accuracy of the edge-weights (solid red line), bootstrapped value (solid black line) 
and the 95% confidence intervals around these edge-weights (gray bars) of the networks for 











Figure 23. Accuracy of the edge-weights (solid red line), bootstrapped value (solid black line) 
and the 95% confidence intervals around these edge-weights (gray bars) of the networks for 
Converters at Time 1- 4 
 
Figure 24. Accuracy of the edge-weights (solid red line), bootstrapped value (solid black line) 
and the 95% confidence intervals around these edge-weights (gray bars) of the networks for Men 








Figure 25. Accuracy of the edge-weights (solid red line), bootstrapped value (solid black line) 
and the 95% confidence intervals around these edge-weights (gray bars) of the networks for 
Women in the Converters group. 
 
Figure 26. Accuracy of the edge-weights (solid red line), bootstrapped value (solid black line) 










Figures 26 – 28 present the bootstrapped difference tests (α = 0.05) between edgeweights 
that were non-zero in the estimated networks and node strength of the nine cognitive tests. In 
these figures, gray boxes indicate nodes or edges that do not differ significantly from one-
another. Black boxes represent nodes or edges that do differ significantly from one another. 
Colored boxes (shades of blue for positive connects and red for negative connections) in the 
edge-weight plot correspond to the strength of the edge in the corresponding network. In these 
figures, the X axis and the Y Axis represents each edge in the network (i.e. the first edge listed is 
the edge between the DIGIFZSCORE and CATFLUENCYZSCORE nodes). When examining 
these tables there are more edges that differ significantly from each other for the networks for the 
Converter group that Control group networks. This difference is particularly notable when 
comparing the Bootstrapped difference tests between edgeweights for the Converter group and 
the Control group at time C, seen in Figure 28. These results suggest that the neurocognitive tests 

















Figure 27. Edge-weights difference test for the network estimated for Controls from time point 1 
to 4. Bootstrapped Difference Test (α = 0.05) between edges-weights that were non-zero in the 
estimated networks.  
 
Note. Black boxes represent edges that differ significantly from one-another, and gray boxes 
indicate edges that do not differ significantly from one-another. Colored boxes in the edge-
weight plot represent the strength of the edge in the networks (Shades of blues represent positive 























Figure 28. Edge-weights difference test for the network estimated for Converters from time point 
1 to 4. Bootstrapped Difference Test (α = 0.05) between edges-weights that were non-zero in the 
estimated networks.  
 
Note. Black boxes represent edges that differ significantly from one-another, and gray boxes 
indicate edges that do not differ significantly from one-another. Colored boxes in the edge-
weight plot represent the strength of the edge in the networks (Shades of blues represent positive 

















Figure 29. Edge-weights difference test for the network estimated for Controls and Converters at 
Time C. Bootstrapped Difference Test (α = 0.05) between edges-weights that were non-zero in 
the estimated networks.  
 
Note. Black boxes represent edges that differ significantly from one-another, and gray boxes 
indicate edges that do not differ significantly from one-another. Colored boxes in the edge-
weight plot represent the strength of the edge in the networks (Shades of blues represent positive 









As can be seen in Tables 4 – 5 and  Figures 32 - 33, over the four time points (Time 1 – 
4) and at the time of conversion (Time C) the cognitive tests that had the highest standardized 
strength for the Control group are Logical Memory I (LOG), Logical Memory II (MEM), and 
Trails B (TRAILB). For example, standardized strengths for Logical Memory I (LOG) for 
controls were: T1 = 1.00, T2 = 0.92, T3 = 0.58, T4 = 0.80, TC =  0.69 (see Table 4 and Figure 
32). Overall, the strength is relatively consistent for all of the cognitive test over the course of the 
four visits for the controls group, however there is more fluctuation in the strength over time for 
the Converter group (see Table 5 and Figure 33). This is particularly noticeable at C time point 
for LOG. More generally, there is greater variability seen across assessment time points for tests 
strongly associated with the dementia process, such as learning and memory (LOG and MEM), 
and sematic fluency (CAT). When the Converter group is subdivided by sex, the highest 
standardized strength for both sexes are again for LOG, MEM, and TRAILB (see Table 6 and 7 
and Figures 34 and 35). These results indicate that LOG, MEM and TRAILB consistently have 
the strongest connections with all other nodes and therefore the greatest influence on the overall 
network structure for all groups. However there appears to be more variability in the strength of 
these nodes for the Converter group over time, suggesting as the dementia process progresses the 
strength of those cognitive tests strongly associated with the dementia process, such as learning 
and memory (LOG and MEM), and sematic fluency (CAT) fluctuates more than is observed in 
the Control group. These results also suggest that there does not appear to be a significant 








Table 4. Strength Centrality for the Control group at each time point. 
Node T1 T2 T3 T4 TC 
BOS -0.53 -0.13 -0.59 -0.50 -0.22 
CAT -2.03 -1.96 -1.96 -1.99 -1.89 
DIGIB 0.49 0.42 0.28 0.39 0.45 
DIGIF 0.09 -0.50 0.22 -0.44 -0.60 
LOG 1.00 0.92 0.58 0.80 0.69 
MEM 0.87 1.23 1.24 1.28 1.46 
NAC -0.91 -0.82 -1.02 -0.39 -0.73 
TRAILA 0.14 0.02 0.53 -0.15 0.02 
TRAILB 0.88 0.82 0.71 1.00 0.83 
Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, 
DIGIB = Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = 
Mini Mental Status Exam, TRAILA = Trails A, TRAILB = Trails B 
 
Table 5. Strength Centrality for the Converter group at each time point. 
Node T1 T2 T3 T4 TC 
BOS -0.91 -0.05 -0.80 -0.80 -0.50 
CAT -0.30 -0.98 -0.32 -0.33 -0.49 
DIGIB -0.29 0.23 -0.37 -0.07 -0.06 
DIGIF -1.18 -1.23 -0.89 -1.54 -1.14 
LOG 1.16 1.31 1.17 0.67 -0.04 
MEM 0.77 0.84 0.93 1.77 1.95 
NAC -0.75 -0.96 -1.28 -0.28 -0.81 
TRAILA -0.25 -0.53 0.00 -0.43 -0.22 
TRAILB 1.74 1.36 1.56 1.02 1.31 
Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, 
DIGIB = Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = 







Table 6. Strength Centrality for the Men from the Converter group at each time point. 
Node T1 T2 T3 T4 TC 
BOS -0.96 -0.60 -0.40 -0.83 -0.39 
CAT -0.17 -0.92 -1.25 -0.77 -0.72 
DIGIB -0.42 0.05 -0.47 -0.46 -0.26 
DIGIF -1.57 -0.94 -0.99 -1.73 -0.91 
LOG 1.42 0.98 1.15 1.07 0.38 
MEM 1.09 1.25 0.79 1.27 1.65 
NAC -0.25 -0.98 -0.67 0.39 -0.59 
TRAILA -0.19 -0.37 0.22 0.43 -0.78 
TRAILB 1.05 1.51 1.62 0.64 1.61 
Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, 
DIGIB = Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = 
Mini Mental Status Exam, TRAILA = Trails A, TRAILB = Trails B 
 
Table 7. Strength Centrality for the Women from the Converter group at each time point. 
Node T1 T2 T3 T4 TC 
BOS -0.57 0.39 -0.94 -0.74 -0.59 
CAT -0.46 -0.79 0.27 0.48 -0.38 
DIGIB -0.25 0.15 -0.34 0.10 0.17 
DIGIF -0.98 -1.55 -0.86 -1.75 -1.45 
LOG 0.94 1.45 1.09 0.57 -0.09 
MEM 0.91 0.60 1.05 1.37 1.93 
NAC -1.15 -0.75 -1.54 -0.19 -0.74 
TRAILA -0.26 -0.66 0.04 -0.89 0.11 
TRAILB 1.82 1.16 1.23 1.06 1.04 
Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, 
DIGIB = Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = 























Figure 32. Strength Centrality analysis of the 9 cognitive domains at each time point for the men 




Figure 33. Strength Centrality analysis of the 9 cognitive domains at each time point for the 








Plot significant differences of the node strength was also performed and the results of this 
test are presented in Figures 33 – 36. Figure 33 shows the significant differences of the node 
strength for the Control group at Time 1 – 4. In Figures 33-36, boxes shaded black represent 
nodes that differ significantly from one another (p < 0.05), while grey boxes represent those 
nodes that do not differ significantly from one another. White boxes contain the specific node 
strength for that node. These figures show that there are more nodes that differ from one another 








































Figure 36. Plot significant differences of node strength (α = 0.05) for controls and converters 




The correlation stability coefficient for strength centrality for Time 1- Time 4 and Time C 
for the Control group was 0.75, 0.75, 0.75, 0.75 and 0.67 (Fig. 36); thus, all time points (Time 1 
– Time 4 and Time C) exceeded the recommended threshold for stable estimation of 0.5 
(Epskamp, Borsboom, & Fried 2018). For the Converter group, the stability coefficient for 
strength centrality for Time 1- Time 4 and Time C for the Control group was 0.67, 0.75, 0.75, 
0.67 and 0.67 (Fig. 37); thus, all time points (Time 1 – Time 4 and Time C) exceeded the 
recommended threshold for stable estimation of 0.5, (Epskamp et al., 2018). When the 







means the centrality estimates in the original network can be considered stable. These results 
indicate the maximum proportion of cases that can be dropped from the sample while 
maintaining a 95 % probability the correlation between original centrality indices and centrality 
of networks based on sample subset. While this parameter can be determined by the research 
based on theoretical factors, it is typically accepted that CS-Coefficient = 0.7 indicates a very 
large effect in the behavioral sciences (Cohen, 1977), while  CS-coefficient should not be below 
0.25, and CS-coefficient above 0.5 are preferable. The CS-coefficients for the current study 
exceeded the 0.5 benchmark for all time points, and therefore the strength centrality estimates in 
the original network can be considered stable. 
 
 
Figure 37. Stability of strength centrality index representing the average correlation of the 










Figure 38. Stability of strength centrality index representing the average correlation of the 
strength centrality index in the networks for the Converter Group from T1 to T4.  
 
 
Figure 39. Stability of strength centrality index representing the average correlation of the 










Figure 40. Stability of strength centrality index representing the average correlation of the 
strength centrality index in the networks for the Women in the Converter Group from T1 to T4.  
 
 
Figure 41. Stability of strength centrality index representing the average correlation of the 










Expected influence is another measure of centrality that provides information about the 
nature and strength of each node’s cumulative influence within the network, while taking into 
account positive and negative relationships. As can be seen in Tables 8 – 12 and Figures 41- 44 , 
over the four time points (Time 1 – Time 4) and at the time of conversion (Time C) the cognitive 
tests that had the highest expected influence for both the Control group and the Converter group 
are Logical Memory I (LOG), and Logical Memory II (MEM). Trails B (TRAILB) also had a 
high expected influence for the Control Group, at all time points, but not for the Converter 
group. When the Converter group is subdivided by sex, Logical Memory I (LOGI) and Logical 
Memory II (MEM) continued to have the highest expected influence for both the men and the 







indicate that LOG and MEM consistently have the highest expected influence on all other nodes 
and therefore the most influence on the overall network structure for all groups, when both 
positive and negative relationships are considered. These results also indicate that TRAILB has a 
high expected influence on all other nodes, for the Control group, although the expected 
influence of this node was not high in the Converter group. As was seen with the strength 
centrality, there appears to be more variability in the strength of these nodes for the Converter 
group over time, suggesting as the dementia process progresses the expected influence on the 
network of those cognitive tests strongly associated with the dementia process, such as learning 
and memory (LOG and MEM) fluctuates more than is observed in the Control group. These 
results also suggest that there does not appear to be a significant difference between men and 









Table 8. Expected Influence Centrality for the Control group at each time point. 
Node T1 T2 T3 T4 TC 
BOS -0.42 -0.08 -0.50 -0.44 -0.37 
CAT -2.01 -2.06 -1.90 -2.06 -1.95 
DIGIB 0.57 0.45 0.39 0.34 0.47 
DIGIF -0.28 -0.43 -0.13 -0.34 -0.52 
LOG 1.01 0.74 0.69 0.80 0.70 
MEM 0.85 1.24 1.37 1.24 1.42 
NAC -0.86 -0.75 -0.94 -0.30 -0.64 
TRAILA 0.22 0.06 0.18 -0.24 0.06 
TRAILB 0.91 0.84 0.83 0.99 0.83 
Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, DIGIB = 
Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = Mini Mental 
Status Exam, TRAILA = Trails A, TRAILB = Trails B 
 
Table 9. Expected Influence Centrality for the Converter group at each time point. 
Node T1 T2 T3 T4 TC 
BOS -1.08 -0.70 -0.33 -0.32 -0.66 
CAT -0.12 0.07 -0.44 -0.38 -0.23 
DIGIB 0.19 0.05 0.14 -0.07 -0.14 
DIGIF 0.23 0.02 -0.02 0.21 0.24 
LOG 1.72 1.60 1.71 1.21 1.04 
MEM 1.13 1.43 1.43 1.84 1.96 
NAC -0.22 -0.61 -0.92 -0.25 -0.18 
TRAILA -0.32 -0.31 -0.24 -0.74 -0.57 
TRAILB -1.53 -1.55 -1.34 -1.50 -1.46 
Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, DIGIB = 
Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = Mini Mental 








Table 10. Expected Influence Centrality for the Men from the Converter group at each time 
point. 
Node T1 T2 T3 T4 TC 
BOS -0.15 -0.82 0.15 -0.16 -0.66 
CAT -0.27 -0.06 -0.73 -0.58 -0.15 
DIGIB -0.47 -0.42 -0.16 -0.14 -0.45 
DIGIF -0.36 0.06 0.32 0.00 0.28 
LOG 2.14 1.49 1.60 1.41 1.18 
MEM 0.96 1.67 1.34 1.84 1.76 
NAC -0.06 -0.62 -0.99 -0.27 -0.02 
TRAILA -0.44 0.02 -0.14 -0.98 -0.30 
TRAILB -1.36 -1.32 -1.39 -1.10 -1.64 
Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, DIGIB = 
Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = Mini Mental 
Status Exam, TRAILA = Trails A, TRAILB = Trails B 
 
Table 11. Expected Influence Centrality for the Women from the Converter group at each time 
point. 
Node T1 T2 T3 T4 TC 
BOS -1.08 -0.18 -0.60 -0.50 -0.61 
CAT -0.16 0.14 -0.24 -0.09 -0.21 
DIGIB 0.55 0.12 0.34 -0.09 0.12 
DIGIF 0.47 0.13 -0.17 0.11 0.16 
LOG 1.31 1.53 1.68 1.29 1.08 
MEM 1.40 1.34 1.50 1.62 1.94 
NAC -0.60 -0.76 -0.77 0.09 -0.31 
TRAILA -0.47 -0.65 -0.50 -0.72 -0.81 
TRAILB -1.43 -1.67 -1.23 -1.71 -1.36 
Note: BOS = Boston Naming Test, CAT = Category Fluency, DIGIF = Digit Span Forward, DIGIB = 
Digit Span Backward, LOG = Logical Memory I, MEM = Logical Memory II, NAC = Mini Mental 







Figure 42. Expected Influence Centrality analysis of the 9 cognitive domains at each time point 
for Control group. 
 
 
Figure 43. Expected Influence Centrality analysis of the 9 cognitive domains at each time point 









Figure 44. Expected Influence Centrality analysis of the 9 cognitive domains at each time point 
for the Men in the Converter group.  
 
 
Figure 45. Expected Influence Centrality analysis of the 9 cognitive domains at each time point 








Temporal Stability of the Network 
 The temporal stability of the network structure was evaluated using the network 
comparison test. Global strength invariance and maximum difference in edge weights was 
examined to determine if and to what degree the Control and Converter groups differed from one 
another at each time point on overall strength of the network and the total difference in edge 
weights.  A centrality difference test was also used to determine if there were significant 
differences in the strength centrality and the expected influence. The results of these analyses are 
presented in Table 12. The findings can be summarized as follows: There was a statistically 
significant difference (p < .05) between the Control and Converter groups for the maximum 
difference in edge weights test at all time points. There was also a statistically significant 
difference (p < .05) between the Control and Converter groups for the global strength test (the 
overall connectivity or density of the network) at Time 2, Time 3, Time 4, and Time C. The 
overall global strength of the networks was not significantly different at Time 1 (p = 0.25). 
When these comparison tests were used to compare the men and women from the Converter 
group, they did not differ significantly on either the global strength test or the maximum 
difference in edge weights test at any of the time points. When the global strength invariance and 
maximum difference in edge weights was examined to determine if and to what degree the 
Converter group differed from one time point to another, they did not differ significantly on 
either the global strength test or the maximum difference in edge weights test at any of the time 
points compared. These results suggest, that there are significant differences in the overall 
network structures between the Control and Converter groups at each time point, except for the 
initial assessment (time 1), when they only differed in terms of the maximum difference in edge 







from one time point to another. With regard to the centrality difference tests, there were 
statistically significant difference between the groups in terms of strength and expected influence 






















Table 12. Results of the network comparison test based on global strength and network invariance 
Group/Time point Global Strength 
p-value 
Maximum difference 
in edge weights 
p-value 
Controls T1 vs Converter T1 0.25 < 0.001 
Controls T2 vs Converter T2 0.04 < 0.001 
Controls T3 vs Converter T3 0.01 < 0.001 
Controls T4 vs Converter T4 0.001 < 0.001 
Controls TC vs Converter TC 0.005 < 0.001 
Converter (Men) T1 vs Converter (Women) T1 0.19 0.55 
Converter (Men) T2 vs Converter (Women) T2 0.73 0.26 
Converter (Men) T3 vs Converter (Women) T3 0.82 0.33 
Converter (Men) T4 vs Converter (Women) T4 0.41 0.96 
Converter (Men) TC vs Converter (Women) TC 0.23 0.99 
Converter T1 vs Converter T2 0.91 0.99 
Converter T1 vs Converter T3 0.37 0.41 
Converter T1 vs Converter T4 0.17 0.45 
Converter T1 vs Converter TC 0.43 0.62 
Converter T2 vs Converter T3 0.32 0.08 
Converter T2 vs Converter T4 0.16 0.60 
Converter T2 vs Converter TC 0.36 0.86 
Converter T3 vs Converter T4 0.51 0.21 
Converter T3 vs Converter TC 0.97 0.61 
Converter T4 vs Converter TC 0.51 0.86 







Chapter 5: Discussion 
 Early detection of individuals who will go on to develop Alzheimer’s disease has been 
the focus of great research interest over the last 30 years for a number of reasons. For example, 
Petersen and colleagues (1994) have long argued that early detection is important because it can 
guide early invention efforts that will allow for preservation of neuronal tissue before significant 
tissue death and atrophy can occur. Early identification is feasible because it has been well 
established that there is a 20-30 year latency between when neuropathological changes first 
begin and when cognitive and functional decline are apparent (Nestor, Fryer, Smielewski, & 
Hodges, 2003; Pengas, Hodges, Watson, & Nestor, 2010). Unfortunately, once cognitive and 
functional declines are apparent and a diagnosis of MCI or Dementia due to AD can be made, the 
amount of cell death and atrophy in the brain is quite advanced and, with today’s treatments, 
irreversible and therefore incurable.  As such, finding ways to detect the presence of AD 
pathology early and stop the progression has been a goal for researchers and clinicians for some 
time now.  
Current work in the early detection focuses on combining results from several different 
bio-behavioral markers to identify individuals who will go on to develop dementia due to 
Alzheimer’s disease at some later point in time. Cognitive tests that are sensitive to the cognitive 
domains affected in AD, such as memory and language abilities (Albert, Moss Tanzi, & Jones, 
2001; Chapuis et al., 2016; Ho, & Nation, for the Alzheimer’s Neuroimaging Initiative, 2018), 
have been used in this effort. Pattern and level of performance on these tests are often combined 
with other early detection methods, such as neuroimaging techniques and genetic testing and 
other bio behavioral markers to identify those individuals that are likely to develop AD (Bondi et 







methods, that can be used in combination with those already developed are still needed to 
improve the efficiency and accuracy of early detection. The current study attempted to further 
these efforts by using a novel approach, network analysis, to examine the multivariate structural 
dependencies among cognitive domains known to be affected in Alzheimer’s disease across four 
serial cognitive assessments, each conducted approximately one year apart, in two groups of 
individuals who were both cognitively normal at baseline assessment. One remained cognitively 
normal over the four-year assessment period and the other demonstrated cognitive decline 
consistent with a diagnosis of mild cognitive impairment or dementia. The use of network 
analysis in this context allows for understanding how associations between tests that are sensitive 
to the neuropathology of AD change within the context of AD pathology in those individuals that 
will go on to be diagnosed with AD, as compared to individuals with normal cognition. The 
addition of network analysis results to other early detection techniques including neuroimaging, 
genetic testing, and other biomarkers may provide even greater power in identifying individuals 
early on in the disease process and allow for earlier interventions which may slow the progress of 
the disease or delay development of cognitive disorder. 
The results of the study suggest that while global differences in network strengths are not 
particularly useful in differentiating individuals at baseline assessment, similar to what might be 
observed when using cognitive screener such as the Mini Mental Status Examination or MoCA, 
differences between strength of associations of individual tasks within the networks were able to 
distinguish individuals who have normal cognitive function at baseline and maintain normal 
function over the four your time period, from those who were normal baseline but went on to 
convert to having a cognitive diagnosis due to AD over the course of 4 years.  They build on 







identification process (Ashendorf et al., 2018; Chapuis et al., 2016; de Paula et al., 2015; Ho et 
al., 2018; Jefferson et al., 2006; Mlinac and Feng, 2016; Razani et al., 2011) by demonstrating 
that not only are absolute scores important as prior studies have shown (Albert et al., 2001; 
Alladi et al., 2007; Chapuis et al., 2016; Clark et al., 2012; Harrington et al., 2013; Ho, & Nation, 
for the Alzheimer’s Neuroimaging Initiative, 2018; Hof et al., 1997; Mendez et al., 2002), but 
the associations between scores in a battery of tests with demonstrated sensitivity to Alzheimer’s 
disease can be informative in identifying those who will develop Alzheimer’s disease as much as 
four years after initial testing when cognition was identified as normal. Furthermore, these 
results may also help explain some of the inconsistent findings reported for cognitive tests when 
used to predict individuals who are at risk for developing Alzheimer’s disease, by suggesting that 
many of the important changes occurring in cognition may not be reflected in overall global 
indicators of cognition or even changes at the test level. Instead, the current results suggest the 
associations between various test scores can aid in distinguishing those that will go on to develop 
AD from those who will not.  
Study Aims and Hypotheses
With regard to study aims, the first major aim of the study was to compare individuals 
that are normal at the initial assessment (Time 1) who then go on to develop either Mild 
Neurocognitive Impairment (MCI) or Major Neurocognitive Impairment (Dementia) due to AD 
at one of the subsequent assessments, to individuals who are normal at baseline and remain free 
of a cognitive diagnosis across all four assessment time points. The second major aim was to 
investigate differences in the network structures of men and women with MCI or dementia due 
to AD over time. Based on these aims, the following hypothesis were made: 1) The overall 







normal cognition as compared to individuals with MCI or Dementia due to AD, at time one, 
prior to meeting criteria for diagnosis; 2) The overall network structure of cognitive domains 
affected in AD will differ for those individuals with normal cognition as compared to individuals 
with MCI or Dementia due to AD after diagnosis of MCI or Dementia due to AD is made; 3) 
The overall network structure for cognitive domains affected in AD will differ for men with MCI 
or Dementia due to AD as compared to women with MCI or Dementia due to AD. 4) The 
Temporal Stability of the network will differ for those with normal cognition who remain normal 
over a four year period, from those individuals who are normal at the initial visit, then go on to 
develop MCI or Dementia due to AD.  
With regard to the first hypothesis, there were notable differences between the Control 
and Converter groups in the overall level of connectivity of the networks, as measured by the 
global strength test, and the maximum difference in edge weights test at all of the time points, 
except for time 1, where only the maximum difference in edge weights differed, which provides 
support for the hypothesis. The significant difference between groups in the maximum difference 
in edge weights indicate subtle difference between those individuals that will go on to be 
diagnosed with MCI or Dementia due to AD and those that remain normal across all four 
evaluations. While these differences do not affect the overall connectedness of the cognitive tests 
and in turn the network structure as measured by the global strength test, there are differences in 
the connections between each node, even before a cognitive diagnosis is warranted. These 
findings suggest that while the overall relationship between the cognitive abilities is not 
significantly different prior to AD diagnosis, there are differences that can be observed, even 
before full diagnostic criteria is met. Previous longitudinal research has reported the expected 







Alzheimer’s disease when compared to those who do not as the diagnosis of dementia becomes 
imminent (Bondi et al., 2008; Menéndez González, 2014). The current study extends these 
results by finding that the differences in network structure between the Control and Converter 
groups became more apparent over the assessment time points, with the greatest difference 
between groups in global network strength occurring at time 4. Future research examining 
additional time points after conversion to a cognitive diagnosis would likely find that these 
differences become even more pronounced as the disease progresses. 
In addition to the difference at time 1 for edgeweight strength, there also were significant 
differences between the groups at all subsequent time points, including the time of conversion, 
both in terms of the overall level of connectivity of the networks, as measured by the global 
strength test, and the maximum difference in edge weights test. These results support the second 
hypothesis, that the two groups network structures would differ once a cognitive diagnosis was 
made. The differences observed in the network structures demonstrates that the 
neurodegenerative process associated with AD gives rise to changes in how various cognitive 
abilities, as measured by neuropsychological tests, relate to one another. More specifically, when 
the connection within the networks estimated were compared, there were strong positive 
relationships between Logical Memory I and Logical Memory II at all time points for both the 
Control and Converter groups. There were also strong positive connections between Trails A and 
Trails B for both groups at all time points. Finally, there was strong positive connections 
between Digits Span Forward (DIGIF) and Digits Span Backward (DIGIB) for the Control group 
at Time 1, Time 2, Time 3 and Time 4, and for the Converter group at Time 3 and Time 4. 
Logical Memory I, Logical Memory II, and Trails B were the cognitive tests with consistently 







group, although more fluctuations in strength centrality were observed in the Converter group. 
These findings were supported by the accuracy analysis. The stability coefficient for strength 
centrality was found exceed the recommended threshold of CS-Coefficient = 0.5 and in some 
cases exceeded the optimal CS-coefficient of 0.7. There were some time points at which the CS-
coefficient was below the optimal threshold of 0.7, including Controls Time C, and Converters 
Time 1, 4 and C. Therefor the network strength was less stable than is considered to be ideal, for 
some time points, however it never fall below the recommended threshold of 0.5, therefore the 
strength centrality estimates in the original network can be considered stable. Increasing the 
sample size in future studies may help to improve the stability of the strength centrality 
coefficient to meet the ideal CS-coefficient of 0.7. The weakening of network association in the 
Converter group as the diagnosis of dementia becomes imminent may correspond to a weakening 
of neural networks necessary to perform well on the tests due to disease progression and 
neuronal death, although this possibility could not be examined in the current study. Future 
research examining associations between neural connectivity using neuroimaging techniques and 
weakening of associations in global network strength for cognitive tests may shed light on this 
matter.  
The current study also examined the network structure of men and women with MCI or 
Dementia due to AD, and based on previous research exploring sex differences in AD predicted 
there would be differences between the network structures of men and women with AD. 
However, this hypothesis was not supported as there were no notable differences observed 
between the overall network structures or the stability of the networks between men and women 
with MCI or dementia due to AD. While substantial research has been conducted examining sex 







and progression of dementia (Hebert et al., 2013; Hebert et al., 2001; Plassman et al., 2007; 
Letenneur et al., 1999; Liu et al., 1998; Kivohara et al., 1996; Mielke et al., 2014; Roberts et al., 
2014; Seshadri et al., 1997), the current results suggest that the network structure of cognitive 
abilities affected by AD does not differ between men and women. These findings are significant 
in that they help to demonstrate the similarities between men and women in terms of how the 
neuropsychological tests results for individuals with AD relate to one another and support the use 
of network analysis in early detection of AD across sex, furthering the generalizability of the 
current findings.  
Structural Importance of Cognitive Tests In the Network 
 When further examining the networks of the Control and Converter groups and the 
structural importance of the various cognitive tests within the networks, there were strong 
positive connections (edge weight > 0.4) observed between Logical Memory I and Logical 
Memory II were expected given Logical Memory II is a measure of information that was learned 
in the Logical Memory I task and retained after a delay. While the overall information learned 
and retained after a delay may decline with the progression of AD (Albert, et al., 2001; Chapuis 
et al., 2016; Ho, et al., 2018), the connection between these tests in the network remained strong 
for both Controls and Converter groups across all time points. A similar pattern was observed in 
the strong positive connections between Trials A and Trails B for both controls and Converter 
groups at all time points. This relationship was also expected given the similarity between these 
tasks, with Trails A measuring processing speed, and Trails B measuring processing speed as 
well as executive functioning. The final strong relationship observed Digits Span Forward, a 
measure of simple attention, and Digits Span Backward, a measure of working memory. These 







Digit Span Forwards and Backwards are indicative of the extra variance explained due to each 
specific ability in these tasks and the variance these tasks account for in the estimated networks. 
There was more variability between the Control and Converter groups for these measures, 
suggesting while a relationship remains between simple attention and working memory in the 
presence of AD pathology, the relationship is less stable than the other cognitive domains 
evaluated in the current study. Results are also consistent with factor analytic studies that 
identify these tests to load on separate factors, and support the distinctions classically drawn 
between cognitive constructs of long-term memory, executive function and working memory, 
and the tests used to assess them. 
As discussed previously, we found there were significant differences between network 
structures for the Control and Converter groups. While relationship between several of the 
cognitive tests remained strong for both groups, there were significant differences between the 
groups on the network comparison tests for the global strength and maximum difference in edge 
weights test for Time 2, 3, 4 and C. At time 1, while there was a significant difference between 
the groups on the maximum difference in edge weights test, there was not a significant difference 
in the global strength test for the two groups. To better understand these differences, the overall 
network structures of the Control and Converter groups at each time point were examined. Based 
on this examination, one striking difference was the number of negative connections present in 
the networks of the Converter group as compared to the Control group. These negative 
relationships are primarily centered around the Trails B test and while none rise to the level of 
being considered strong negative connections (edge weight > - 0.4), there are several considered 
moderate negative connections (edge weight > - 0.1). This appears to become more prominent in 







negative relationships in the network in the presence of AD pathology represents a change in 
how the cognitive abilities assessed by the tests relate to one another. Generally, we expect to see 
positive relationships between cognitive abilities, as the different abilities support or mutually 
reinforce each other. In the case of a negative partial correlation between Trails B and the other 
abilities, this suggests performance on Trails B is not mutually reinforcing the other abilities in 
those that Convert to AD. Trails B is a measure of executive functioning that is most affected 
later in the progression of AD, although these findings suggest that its role in the network 
structure changes even before diagnosis is made and impairments in executive functions are 
apparent. This is likely related to the neuroanatomical changes that occur as the disease 
progresses and consistent with the greater role of the disease process on neuropsychological test 
performance as the AD pathology progresses. The influence of other variables, such as age, sex, 
level of education, etc., which contribute to individual differences among those with normal 
cognition are progressively diminished as the AD pathology progresses and increasing amount of 
neural tissue is compromised.  As discussed previously, there are specific regions of the brain 
(i.e. medial temporal lobes and progresses frontally) known to atrophy as AD progresses (Korf, 
et al., 2004; Nestor et al., 2003; Pengas et al., 2010). This atrophy results in declines in the 
cognitive abilities mediated by those regions (Hebert et al., 2003). In turn, the nature of the 
relationship between those affected cognitive abilities would be expected to change. As 
mentioned, Trails B is considered a measure of executive functioning, and is thought to be a 
general indicator of the biological status of the brain that declines as the neuropathology load 
become greater. When taken together the differences between the network structures of Controls 







impacted by AD relate to one another in the presence of a disease process known to negatively 
impact those cognitive domains.  
The final hypothesis, which posited changes over time in the network structure of those 
with AD, was only partially supported. Although there was a progressive decrease in network 
strength in the Converter group from time 1 to time 4, these differences were not statistically 
significant. Comparisons between time 1 and time 2 suggested little if any difference in network 
strength (p = .91), with larger but still nonsignificant differences present when time 1 was 
compared to time 3 (p = .37), and to time 4 (p = .17). The trend noted in these results suggest that 
this hypothesis may not have been fully supported because of the limited duration of the study 
data. Given this trend, if a fifth assessment was available, it is quite possible that a significant 
difference in network structure would have been identified from time 1 to time 5. It was also the 
case that only 17.8% of the Converter group had a cognitive diagnosis of dementia, while the 
others were diagnosed with mild cognitive impairment. Greater differences in network structure 
over time may also have been observed if all individuals in the Converter group developed 
dementia over the 4 year period. AD is a disease that progresses on average over the course of 10 
years (Warner & Butler, 2000) and for some individuals, particularly those with high levels of 
cognitive reserve, significant cognitive declines only occur in the later years of the disease. 
Given that the current study included individuals who were normal at baseline and followed 
them for 4 years, it is not surprising that many of the individuals in the Converter group did not 
progress to full dementia. The 4 year period was selected to ensure there were enough 
participants for network analyses.  However, it seems likely that the duration of the current 
study, while useful in understanding differences in the networks prior to formal cognitive 







process. Future research could examine these same individuals at subsequent time points (if 
retained in the study) to examine if significant differences in the networks arise within the 
Control groups network structure as the disease has progressed and the cognitive abilities 
measured have further declined.  
Limitations and Future Directions 
 Some limitations should be taken into account when interpreting the results of the current 
study. Firstly, the demographic representation of the participants is limited in terms of diversity, 
such that the sample is comprised of primarily White individuals with an average education of 
15.7 years. Previous research has demonstrated differences in performance on cognitive tests 
between individuals of different races who are at risk or who have developed Alzheimer’s 
disease (Heaton, Ryan, & Grant, 2009; Kim et al., 2017; Rilling et al., 2005; Smith, Wong, Ivnik 
& Malec, 1997). These studies examined performance at the test score or global index level, as 
opposed to the network level as done in the current study. As such, it remains to be seen whether 
there will be differences in network structure that might be attributable to differences in race or 
ethnicity. Future research should examine this matter. A number of factor analytic studies 
indicate that the latent structure of well-validated cognitive tests such as IQ tests typically 
generalize well across different racial and ethnic groups, even when group differences are 
present in overall level of performance. Since network analysis focuses on the relationships 
between tests similar to factor analysis, it is possible that different racial groups would 
demonstrate similar patterns in network structures despite overall differences in level of 
performance. If this were the case, then examining cognitive networks as an early detection 
technique may generalize well across different racial and ethnic groups. In any case, in order for 







education, direct comparisons of network structure are needed.   
 Another limitation of the current study involves the parameter stability of the network.  
While a sample of 432 controls and 432 converters is relatively large in terms of psychological 
research studies, in regularized partial correlation models/network analysis a large number of 
parameters are estimated (Epskamp & Fried, 2018). Therefore, despite the fact that the current 
study is based on 864 participants (432 per group) and showed at least moderate stability and 
accuracy, these results should be considered preliminary in nature and should be replicated with 
other large samples. Future research in this area would benefit from including more participants 
from more diverse backgrounds.  
Finally, since the development of the NACC database, there has been additional cognitive 
tests found to be helpful in identifying cognitive decline due to AD pathology. As such, the 
NACC UDSNB has been updated over the years and is now on the third version, UDSNB 3.0. 
This new version now includes a measure of visuospatial construction and memory, processing 
speed, and phonemic fluency. These measure were only available for a limited number of our 
participants at the later time points, and were therefore not able to be included in the current 
study. Given their sensitivity to AD, the addition of these additional tests could help to provide a 
network structure that is more useful in understanding the relationship between cognitive 
abilities within the context of AD. Similarly, because the current tests were selected for their 
known sensitivity to Alzheimer’s disease, the results may vary substantially when other 
neuropsychological tests are used, i.e., differences between groups may be more or less apparent 
in network structure depending on the tests include in the assessment. Future studies would 
benefit from including these additional tests, as available. Despite these limitations, the current 







providing a clearer understanding the impact of AD on the changes in cognitive functioning to 
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EDUCATION  
Doctor of Philosophy              Anticipated Graduation: August 2020 
University of Nevada, Las Vegas (UNLV)                Advisor: Daniel N. Allen, Ph.D. 
 
APA-Accredited Clinical Psychology Program, Neuropsychology Track  
Dissertation: Network Analysis of Cognitive Symptom Domains in Alzheimer's Disease 
(AD) 
 
Masters of Arts in Psychology             May, 2017 
University of Nevada Las Vegas (UNLV)            Advisor: Daniel N. Allen, Ph.D. 
 
APA-Accredited Clinical Psychology Program, Neuropsychology Track  
Thesis: Neurocognitive Correlates of the Comprehensive Trail Making Test (CTMT) in 
Brain Injured Children 
 
Bachelor of Science in Psychology               December, 2011 
Texas State University- San Marcos              Advisor: Reiko Graham, Ph.D. 
Magna Cum Laude 
 
 
CLINICAL INTERNSHIP  
VA North Texas Health Care System     July 2018 - July 2018 
APA-Accredited Clinical Internship, Neuropsychology Track 
Primary Supervisor: Barry Ardolf, Psy.D., ABPP-CN 
 
• Neuropsychology Consult Team                      July 2018 - October 2018 
Major Rotation                                            Supervisor: Barry Ardolf, Ph.D., ABPP-CN 
o Outpatient comprehensive neuropsychological assessments, interviewing, and 
report writing adult and geriatric populations for veterans diagnosed with medical 
or neurological conditions and/or comorbid psychiatric conditions such as 
neuropsychiatric disorders, dementias, stroke, traumatic brain injury, chronic 
pain, PTSD, depression, anxiety, and pre- and post-surgical evaluations for 









• Spinal Cord Injury Center                                       October 2018 - January 2019 
Major Rotation                                                            Supervisor: Emma Shapiro, Ph.D. 
 
o 30-bed inpatient unit to care for the medical and rehabilitation needs of persons 
with spinal cord injuries or other neurological dysfunctions (e.g., Multiple 
Sclerosis, Guillain-Barre Syndrome, and cervical myelopathy) as well as an 
outpatient clinic for comprehensive care throughout the lifespan. Inpatient and 
outpatient rehabilitation psychology. Experiences included working within an 
interdisciplinary team addressing behavioral medicine issues, neuropsychological 
disorders, behavioral issues, and psychological disorders within a specialized 
medical unit. Services include bedside assessments, neuropsychological 
assessments, comprehensive assessments of an individual’s coping status and 
adaptation to chronic illness and disability in the context of personality, cognitive 
status, as well as family and social systems in order to implement an appropriate 
treatment plan 
 
• Mental Health Silver Team          January 2019 - April 2019 
Major Rotation                                             Supervisor: Heejin Kim, Psy.D. ABPP-CN 
o Geriatric Specialty clinic for patients age 62 and older are assigned to this team 
for their care regardless of their psychiatric diagnosis. Experiences will include 
cognitive screening, interviewing, neuropsychological assessment, report writing, 
and provisions of feedback.  
 
• Community Living Center – Hospice Care              January 2019 - April 2019 
Minor Rotation                                                          Supervisor: Mallory Lamb, Psy.D.  
o 120-bed extended care facility which provides interdisciplinary medical 
rehabilitation, long-term residential care, and hospice care. The CLC includes a 
CARF-accredited program for acute-intensive rehabilitation for survivors of 
serious injury or illness. Veterans admitted for rehabilitation often present with 
orthopedic injuries, amputation, stroke, and other medical and neurological 
conditions along with adjustment, mood, and behavioral concerns that may impact 
recovery. Veterans admitted for hospice care have a terminal diagnoses (e.g., 
cancer, COPD) with typical life-expectancy of less than six months. Experiences 
include supportive therapy with Veterans and their family. 
 
• Mental Health Inpatient Unit                            April 2019 - July 2019 
Major Rotation                                                                   Supervisor: Aletha Miller, Ph.D.  
o Inpatient psychiatric unit for acute treatment of severe psychopathology. Services 
provided include group and individual therapy interventions that contribute to 
remediation of acute symptoms. Interventions consist primarily of primarily 








PRACTICUM EXPERIENCES  
Cleveland Clinic Lou Ruvo Center for Brain Health          June 2016 - July 2017 
Las Vegas, NV       
Supervisors: Sarah Banks, Ph.D. ABPP-CN, Justin B. Miller, Ph.D., ABPP-CN, Jessica Z. 
Caldwell, Ph.D. ABPP-CN         
Pre-Doctoral Practicum Student  
• Conducted comprehensive neuropsychological assessments with adult individuals in an 
outpatient specialized medical clinic.  
o Scoring, interpretation, interviewing (under live supervision), and comprehensive 
report writing. 
• Commonly presented patient diagnoses including individuals suspected of having 
neurodegenerative disease, particularly dementias, movement disorders, and multiple 
sclerosis referred from neurology and psychiatry. 
• Co-facilitated a weekly support group for caregivers with a psychologist.  
• Weekly individual supervision meetings in addition to weekly case conferences and 
group supervision with neuropsychology supervisors, post-doctoral fellows, and students. 
• Weekly case conferences, didactics, or grand rounds with neurology, physical therapy 
and/or social work. 
Neuropsychology Technician      July 2017 - June 2018 
• After formal practicum training ended, hired to continue conducting neuropsychological 
assessments, scoring, and report writing on an as-needed basis. 
 
 
Center for Applied Neuroscience    May 2015 - August 2016 
Las Vegas, NV                 
Supervisors: Thomas F. Kinsora, Ph.D., and Sharon Jones-Forrester, Ph.D. 
Pre-Doctoral Practicum Student  
• Conducted neuropsychological and forensic assessments with children and adults in an 
outpatient private practice setting or the Clark County Detention center. 
• Responsibilities included scoring, interpretation, integrative report writing, participation 
in intake interviews and feedback sessions, as well as record review. 
• Commonly presented patient diagnoses included cognitive disorders of varying 
etiologies, affective disorders, pervasive developmental disorders, learning disabilities, 
and TBI. 
• Weekly individual supervision and group supervision, as well as didactic training and 
case conferences.  
• Saw Active-duty service member patients referred for neuropsychological evaluation for 
combat-related injuries including TBI, polytrauma, PTSD, for Medical Evaluation Board, 
and Aeromedical Waiver evaluations. 
 
Testing Assistant      August 2016 - June 2018 
• After the formal practicum training ended, hired to continue conducting 








Disability Resource Center (DRC)/Academic Success Center  
        May 2016 - August 2017  
        Supervisor: Michelle Paul, Ph.D. 
 Graduate Assistant  
• Administered, interpreted, and wrote integrated psychoeducational and 
neuropsychological evaluations for UNLV students presenting with academic difficulties 
to determine eligibility for accommodations.  
• Participated as a consultant to DRC staff in weekly documentation review meetings 
regarding eligibility for academic accommodations.  
• Diagnoses included: Specific Learning Disorders, Attention-Deficit Hyperactivity 
Disorder, Borderline Intellectual Functioning, Language Disorder, Autism Spectrum 
Disorder, Unspecified Neurodevelopmental Disorders, Neurocognitive Disorder, 
Depressive Disorders, Anxiety Disorders, Bipolar I Disorder, Posttraumatic Stress 
Disorder, Eating Disorders, and Substance Use Disorders. 
 
The Partnership for Research, Assessment, Counseling, Therapy, and Innovative Clinical 
Education (The PRACTICE)         August 2014 - August 2015  
        May 2017- August 2017  
        Supervisor: Michelle Paul, Ph.D. 
Pre-Doctoral Practicum Student  
• Provided individual psychotherapy to a caseload of approximately 4-7 patients per week. 
• Conducted clinical intakes. 
• Patients included adolescents and adults of diverse cultural backgrounds from the 
community. 
• Diagnoses seen included affective disorders, adjustment disorders, trauma, and severe 
mental illness, including bipolar disorder and delusional disorder.  
• Theoretical approach was integrative, including biopsychosocial, CBT, and interpersonal 
orientations and aspects of DBT and ACT.  
 
Psychological Assessment and Testing Clinic   sAugust 2014 – August 2015  
University of Nevada Las Vegas            
Supervisor: Michelle Paul, Ph.D. 
 
Pre-Doctoral Practicum Student 
• Conducted comprehensive neuropsychological and psychoeducational assessments, used 
a flexible battery approach, for adult patients referred from the community and the 
university disability resource center.  
• Conducted intake interview and feedback sessions. 











PUBLICATIONS AND PRESENTATIONS  
Manuscripts Published 
Parke, E. M., Becker, M. L., Graves, S. J., Baily, A. R., Paul, M. G., Freeman, A. J., & Allen, D. 
N. (2018). Social Cognition in Children With ADHD. Journal of Attention Disorders. 
Mayfield, A. R., Parke, E. M., Barchard, K. A., Zenisek, R. P., Thaler, N. S., Etcoff, L. M., & 
Allen, D. N. (2016). Equivalence of mother and father ratings of ADHD in 
children. Child neuropsychology, 1-18. 
Parke, E. M., Mayfield, A. R., Barchard, K. A., Thaler, N. S., Etcoff, L. M., & Allen, D. N. 
(2015). Factor structure of symptom dimensions in attention-deficit/hyperactivity 
disorder (ADHD). Psychological Assessment, 27(4), 1427-1437. 
Ceballos, N., Mayfield, A. R., & Graham, R.(2015). ERPs to alcohol images among Hispanic 
and non-Hispanic female college freshmen. AIMS Neuroscience, 3(1), 1-21. 
doi:10.3934/Neuroscience.2016.1.1 
Manuscript Submitted 
Baily, A. R., Lee, B. G. Donohue, B., Mayfield, J. W., Allen, D. N., (re-submitted with revision) 
Neurocognitive predictors of executive function deficits in children with brain disorders.  
Manuscript in Preparation 
Nunez, A., San Miguel, L. Mayfield A. R., Allen, D. N., Donohue, B., Barchard, K. (in 
preparation). Short form validity of the Spanish and English versions of the Wechsler 
Intelligence Scales for Children-Fourth Edition (WISC-IV) in a clinical sample.  
Presentations 
Mayfield, A. R., Lee, B.G., Mayfield, J.W., & Allen, D.N., (2016). Neurocognitive Correlates of 
the Comprehensive Trail Making Test (CTMT) in Children with Neurological Disorders. 
Poster presented at the National Academy of Neuropsychology 36th Annual Meeting, 
Seattle, Washington. 
Mayfield, A. R., (2016). Neurocognitive Correlates of the Comprehensive Trail Making Test 
(CTMT) in Brain Injured Children. Presentation conducted at the University of Nevada 
Las Vegas psychology graduate research data blitz symposium.  
Mayfield, A.R., Ciobanu. C., Etcoff. L., & Allen, D.N., (2015). Utility of WISC-IV Short Forms 
in Attention-Deficit/Hyperactivity Disorder (ADHD). Poster presented at the National 
Academy of Neuropsychology 35th Annual Meeting, Austin, Texas. 
Mayfield, A.R., Reyes, A., Mayfield, J.W., & Allen, D.N., (2014). Improvement in Executive 
Function Following Traumatic Brain Injury (TBI) in Children. Poster presented at the 
National Academy of Neuropsychology 34th Annual Meeting, Fajardo, Puerto Rico. 
Mayfield, A.R., Reyes, A., Mayfield, J.W., & Allen, D.N., (2014). Improvement in Executive 







the University of Nevada Las Vegas Graduate & Professional Student Association 
Research conference. 
Mayfield, A.R., Ceballos, N.A., & Graham, R. (2013). Alcohol-related attentional biases in 
female college freshman: A cross-cultural ERP study. Alcohol-related attentional biases 
in female college freshman: A cross-cultural ERP study. Presented at the Cognitive 
Neuroscience Society meeting in San Francisco, California. 
Dodwell, G., Mayfield, A.R., Ceballos, N.A., & Graham, R. (2013). Gaze cuing elicited by 
gazing expressive faces and alcoholic/non-alcoholic targets in social drinkers. Presented 
at the Cognitive Neuroscience Society meeting in San Francisco, California. 
Ceballos, N.A., Mayfield, A.R., Paz, J.M., Vela-Gude, M.L., Graham, R. (2012). A cross-
cultural study of automatic and controlled processing of alcohol images in female college 
freshman. Poster presented at the 52nd annual meeting of the Society for 
Psychophysiological Research, New Orleans, Louisiana.  
 
Graham, R., Mayfield, A.R.,. & Ceballos, N.A. (2012). A longitudinal cross-cultural study of 
automatic and controlled processing of alcohol images in female college freshmen. Paper 
presented at TM’s 1st World Neuroscience Online Conference.  
  
Graham, R., Mayfield, A.R., & Ceballos, N.A. (2012). A longitudinal cross-cultural study of 
automatic and controlled processing of alcohol images in female college freshmen. Paper 
presented at TM’s 1st World Neuroscience Online Conference.  
 
Reiter, K., Mayfield, A.R., & Graham, R. (2012). Event-Related Potentials to Static and 
Dynamic Expressive Faces. Health Psychophysiology Lab, Department of Psychology. 
Poster presented at the Cognitive Neuroscience Society Meeting, Chicago, Illinois.  
 
Abstracts 
Mayfield, A. R., Lee, B.G., Mayfield, J.W., & Allen, D.N., (in press). Neurocognitive Correlates 
of the Comprehensive Trail Making Test (CTMT) in Children with Neurological 
Disorders. Archives of Clinical Neuropsychology. 
Mayfield, A.R., Ciobanu. C., Etcoff. L., & Allen, D.N., (in press). Utility of WISC-IV Short 
Forms in Attention-Deficit/Hyperactivity Disorder (ADHD). Archives of Clinical 
Neuropsychology. 
Mayfield, A.R., Reyes, A., Mayfield, J.W., & Allen, D.N., (in press). Improvement in Executive 
Function Following Traumatic Brain Injury (TBI) in Children. Archives of Clinical 
Neuropsychology. 
Ceballos, N. A., Mayfield, A. R., Paz, J. M., Vela-Gude, M. L., & Graham, R. (2012). A Cross-
Cultural Study of Automatic and Controlled Processing of Alcohol Images in Female 







Mayfield, A., Ceballos, N., & Graham, R. (2013). Alcohol-related Attentional Biases in Female 
College Freshman: A Cross-Cultural ERP Study. In Journal of Cognitive 
Neuroscience (pp. 211-211).  
 
RESEARCH EXPERIENCE  
Neuropsychology Research Program         August 2013 - July 2018 
University of Nevada, Las Vegas           Advisor: Daniel N. Allen, Ph.D. 
 
Graduate Research Assistant             August 2013 - July 2018 
• Collaborated in research related to neuropsychology. 
• Conducted research related to cross cultural neuropsychology. 
• Conducted literature reviews, write, and review manuscripts. 
• Assisted in training of other students with IRB, statistics, etc. 
• Conducted psychological assessments. 
Relevant Projects 
Study (dissertation): Network Analysis of Cognitive Symptom Domains in Alzheimer's 
Disease (AD) 
• Responsibilities include project development, selection of study variables, proposal 
presentation and database acquisition. Additional responsibilities will include 
conducting literature review, statistical analysis and interpretation. 
 
Study (thesis): Neurocognitive Correlates of the Comprehensive Trail Making Test 
(CTMT) in Brain Injured Children 
• Responsibilities included project development, database management, selections and 
completion of statistically analyses, and manuscript preparation. 
 
Study: Standardization of the Wechsler Intelligence Scale for Children, Fifth Edition 
(WISC-V). 
• Responsibilities included recruiting, screening, and assessing children with traumatic 
brain injury, intellectual disability, and attention-deficit/hyperactivity disorder with 
the standardization version of the WISC-V to assist Pearson in establishing 
normative data. 
 
Study: Standardization of Halstead Category Test, Computer Version. 
• Responsibilities included training undergraduates and coordinating assessments of 
individuals from the UNLV Psychology subject pool in a two-part 
neuropsychological battery. Measures included the Halstead Category Test 
(computer and original version), and measures of intellectual functioning, executive 
functioning, motor functioning, and attention. 
 
Study: Social Cognition in children with ADHD 







extensive neuropsychological battery to assess social cognitive functioning 
 
Event Related Potential Laboratory             2011-2013 
Texas State University- San Marcos    Advisor: Reiko Graham, Ph.D. 
 
Event Related Potentials (ERP) Laboratory Coordinator                                 
• EEG capping, administration of study protocol, data collection, data pre-processing, 
data processing, data plotting. 
 
Salivary Analysis Laboratory Assistant                                                         




TEACHING EXPERIENCE  
University of Nevada Las Vegas     August 2016 - May 2018 
Las Vegas, NV 
 
Instructor  
• PSY 101 General Psychology  
o Designed and taught two sections of course per semester. 
o Prepared all course material, lecturing, assigning class grades, and advisement of 
students. 
 
• PSY 451 Introduction to Principals of Psychotherapy 
o Designed and taught two sections of course per semester. 





National Academy of Neuropsychology            2015-2017 
Awards Committee - Student Member        
 
UNLV Outreach Undergraduate Mentorship Program          August 2013 - May 2018 
Provided mentorship of undergraduate students from underrepresented populations to 
prepare them for a career in psychology or a related field.  
 
Chair, Clinical Student Committee           August 2016 - May 2017 
Responsibilities included attending faculty meetings, assisting with interview weekend 
activities, organizing student focused events, and serving as a liaison between clinical 
faculty and graduate students. 
 







Served as the student representative on the advisory board for the UNLV Partnership for 
Research, Assessment, Counseling, Therapy, and Innovative Clinical Education, The 
PRACTICE, is a community mental health training clinic. The advisory board works on 
planning and program development for the PRACTICE.  
 
FURTHER TRAINING AND CERTIFICANTION  
 
Nevada Psychological Association Comprehensive Training in Dialectical Behavior 
Therapy (DBT), Las Vegas, NV  Presenter/Instructor: Alan Fruzzetti, Ph.D. 
• Completed Part I: Theory, Structure, Targets, and Treatment Strategies, Feb. 5th – 7th, 
2015 
• Completed Part II:  DBT Skills, Skill Training & Skill Coaching, Apr. 16th – 18th, 2015 
 
SCID Training Program                Fall 2015-Spring 2016 
University of Nevada, Las Vegas               Training Supervisor: Daniel N. Allen, Ph.D. 
• Completed a 40-hour training program for administration of the Structured Clinical 
Interview of the DSM-IV-TR Axis I Disorders (SCID-IV).  
 
Symptoms Rating Training Program           Fall 2015 – Spring 2016 
University of Nevada, Las Vegas             Training Supervisor:  Daniel N. Allen, Ph.D. 
• Completed a 30-hour training program for the administration of several of clinician 
administered symptom scales associated with symptoms of schizophrenia and bipolar 
disorder.  
 
The Collaborative IRB Training Initiative (CITI) Program           Fall 2013 - Present 
• Certified to work with human participants through The Protection of Human Research 




HONORS AND AWARDS  
Barrick Graduate Fellowship                   2017-2018 
This fellowship is awarded to outstanding doctoral  
students who have demonstrated excellence in scholarship during their graduate  
study at UNLV. These fellowship awards provide a $15,000 stipend;  
full tuition and fees paid up to 9 credits per semester, full health insurance 
benefits, and a waiver of out-of-state tuition, if applicable. 
 
Graduate & Professional Student Association travel funding         2016 
Awarded funding to attend and present at The National Academy of Neuropsychology  
36th Annual Convention, Seattle, WA ($700). 
  







Awarded funding to attend and present at The National Academy of Neuropsychology  
35th Annual Convention, Austin, Texas ($750). 
 
Graduate & Professional Student Association travel funding         2014 
Awarded funding to attend The National Academy of Neuropsychology  
34th Annual Convention in Fajardo, Puerto Rico ($800).  
 
Graduate Access Grant ($2,000)                         2013 - 2017 
 
Member, Psi Chi the National Honor Society in Psychology                  2008 - 2011 
 
 
AFFILIATIONS AND ACTIVITIES  
 
Member, American Psychological Association                2013 - present 
 
Member, National Academy of Neuropsychology      2013 - present 
 
Member, Nevada Psychological Association                 2013 - present 
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